Unnamed: 0 int64 0 2.34M | titles stringlengths 5 21.5M | abst stringlengths 1 21.5M |
|---|---|---|
2,336,800 | A computational resource for the prediction of peptide binding to Indian rhesus macaque MHC class I molecules. | Non-human primates, in general, and Indian rhesus macaques, specifically, play an important role in the development and testing of vaccines and diagnostics destined for human use. To date, several frequently expressed macaque MHC molecules have been identified and their binding specificities characterized in detail. Here, we report the development of computational algorithms to predict peptide binding and potential T cell epitopes for the common MHC class I alleles Mamu-A*01, -A*02, -A*11, -B*01 and -B*17, which cover approximately two thirds of the captive Indian rhesus macaque populations. We validated this method utilizing an SIV derived data set encompassing 59 antigenic peptides. Of all peptides contained in the SIV proteome, the 2.4% scoring highest in the prediction contained 80% of the antigenic peptides. The method was implemented in a freely accessible and user friendly website at . Thus, we anticipate that our approach can be utilized to rapidly and efficiently identify CD8+ T cell epitopes recognized by rhesus macaques and derived from any pathogen of interest. |
2,336,801 | Alpha-1-antichymotrypsin (ACT or SERPINA3) polymorphism may affect age-at-onset and disease duration of Alzheimer's disease. | In addition to genetic effects on disease risk, age-at-onset (AAO) of Alzheimer's disease (AD) is also genetically controlled. Using AAO as a covariate, a linkage signal for AD has been detected on chromosome 14q32 near the alpha1-antichymotrypsin (ACT) gene. Previously, a signal peptide polymorphism (codon -17A>T) in the ACT gene has been suggested to affect AD risk, but with inconsistent findings. Given that a linkage signal for AAO has been detected near ACT, we hypothesized that ACT genetic variation affects AAO rather than disease risk and this may explain the previous inconsistent findings between ACT genetic variation and AD risk. We examined the impact of the ACT signal peptide polymorphism on mean AAO in 909 AD cases. The ACT polymorphism was significantly associated with AAO and this effect was independent of the APOE polymorphism. Mean AAO among ACT/AA homozygotes was significantly lower than that in the combined AT+TT genotype group (p = 0.019) and this difference was confined to male AD patients (p = 0.002). Among male AD patients, the ACT/AA genotype was also associated with shorter disease duration before death as compared to the ACT/AT+TT genotypes (p = 0.012). These data suggest that the ACT gene may affect AAO and disease duration of AD. |
2,336,802 | Emotional reactions to predictive testing in Alzheimer's disease and other inherited dementias. | This work describes the reasons and emotional responses of healthy descendants after counseling for presenilin mutations in early-onset familial Alzheimer's disease (EOFAD), tau mutations in familial frontotemporal dementia (FTD), and prion mutations in fatal familial insomnia (FFI). A multidisciplinary protocol following Huntington's disease counseling guidelines and a post-test follow-up program were developed to counsel healthy descendants of affected families. The psychological consequences, anxiety levels, and depression status were assessed through validated scales before and after disclosing the information. Nine people from three different families, one with EOFAD, another with FTD, and the other with FFI came for counseling. Their main reason for testing was to initiate early treatment in the future. Disclosing the information decreased anxiety in two carriers, increased it temporarily in one, and had no effect in another. All noncarriers felt relieved. Overall, after a mean of 30 months of follow-up, no negative psychological reactions were observed. All participants positively valued the program. Although preliminary, our observations suggest that predictive testing in EOFAD, FTD, and FFI is safe and may be of benefit when performed with a delicate approach under strict pretest counseling protocols and post-test follow-up programs. The emotional reactions were similar, although the diseases, their phenotype, and mutation characteristics were different. |
2,336,803 | Positive genetic correlations among major life-history traits related to ecological success in the aphid Myzus persicae. | Life-history theory is based on the assumption that evolution is constrained by trade-offs among different traits that contribute to fitness. Such trade-offs should be evident from negative genetic correlations among major life-history traits. However, this expectation is not always met. Here I report the results of a life-table experiment designed to measure the broad-sense heritabilities of life-history traits and their genetic correlations in 19 different clones of the aphid Myzus persicae from Victoria, Australia. Most individual traits, as well as fitness calculated as the finite rate of increase from the life table, exhibited highly significant heritabilities. The pattern of genetic correlations revealed absolutely no evidence for life-history trade-offs. Rather, life histories were arranged along an axis from better to worse. Clones with shorter development times tended to have larger body sizes, higher fecundities, and larger offspring. The fitness of clones estimated from the life table in the laboratory tended to be positively associated with their abundance in the field. Fitness also increased significantly with heterozygosity at the seven microsatellite loci that were used to distinguish clones and estimate their frequencies in the field. I discuss these findings in light of a recent proposition that positive genetic correlations among life-history traits for which trade-offs are expected can be explained by genetic variation for resource acquisition ability that is maintained in populations by a cost of acquisition, and I propose ways to test for such a cost in M. persicae. |
2,336,804 | Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. | Identifying BRCA1 and BRCA2 mutation carriers is increasingly important as new management options show promise in decreasing morbidity and mortality in these women. The authors sought to determine the prevalence of family histories suggestive of a hereditary breast carcinoma syndrome in a cohort of patients with a personal history of breast and/or ovarian carcinoma presenting for mammography.</AbstractText>The authors reviewed the family histories of all women with a history of breast or ovarian carcinoma presenting for mammography over a 37-week period. Using the Myriad model, the authors evaluated the prevalence of family histories with a > or = 10% risk of a BRCA1 or BRCA2 mutation.</AbstractText>During the period of the current study, 14,597 women completed a family history questionnaire. Of these women, 1764 had a personal history of breast or ovarian carcinoma, 86.6% had unilateral breast carcinoma, 4.6% had bilateral breast carcinoma, 8.2% had ovarian carcinoma, and 0.5% had both breast and ovarian carcinoma. Overall, 20.6% met the criteria for a > or = 10% risk of mutation according to the Myriad model. This incidence was higher among Ashkenazi women (47.3%) and among patients with a personal history of ovarian carcinoma (35.9%).</AbstractText>Application of the Myriad model to women with a personal history of breast and ovarian carcinoma suggested that approximately 1 in 5 of these women (20.6%) will have family histories suspicious for a genetic mutation. This risk was higher for Ashkenazi women and for those with a personal history of ovarian carcinoma. This prevalence was considerably higher than the rate reported among women with no personal history of cancer, and has significant implications for their management, as well as for the capacity for risk assessment and testing.</AbstractText>(c) 2005 American Cancer Society.</CopyrightInformation> |
2,336,805 | The incidence of Lynch syndrome. | Lynch syndrome (LS) here is defined as carriership of a deleterious mismatch repair (MMR) gene mutation. By screening for MMR gene mutations in unselected colorectal or endometrial cancer patients, it was found that the prevalence of LS in colorectal and endometrial cancer patients is 1-3%. On extrapolation to the entire population, the incidence of LS is between 1:2000 and 1:660. As all screening methods are less than 100% sensitive, the above figures are underestimates. |
2,336,806 | Glucose-6-phosphate dehydrogenase (G6PD) mutations in Cambodia: G6PD Viangchan (871G>A) is the most common variant in the Cambodian population. | We conducted a survey of malaria diagnoses and glucose-6-phosphate dehydrogenase (G6PD) testing in remote areas of Cambodia. Blood specimens from 670 people were collected by the finger-prick method. Of these people, 24.9% were found to have malaria, and 7.0% of people were G6PD deficient. In the Khmer, the largest ethnical population in Cambodia, the G6PD deficiency rate of males was 12.6% (25/199) whereas the rates in the minorities of the Tum Pun and the Cha Ray were 1.1% (1/93) and 3.2% (2/63), respectively. Of the G6PD-deficient subjects, 97.9% (46/47) were G6PD Viangchan (871G>A), and only one case (2.1%) was G6PD Union (1360C>T). Since G6PD Mahidol (487G>A) is common in Myanmar according to our previous study, the current finding suggests that the Cambodian population is derived from homogeneous ancestries and is different from the Myanmar population. All G6PD Viangchan cases were linked to two other mutations of 1311C>T and IVS-11 nt93T>C in the G6PD gene. |
2,336,807 | Transgenic watermelon rootstock resistant to CGMMV (cucumber green mottle mosaic virus) infection. | In watermelon, grafting of seedlings to rootstocks is necessary because watermelon roots are less viable than the rootstock. Moreover, commercially important watermelon varieties require disease-resistant rootstocks to reduce total watermelon yield losses due to infection with viruses such as cucumber green mottle mosaic virus (CGMMV). Therefore, we undertook to develop a CGMMV-resistant watermelon rootstock using a cDNA encoding the CGMMV coat protein gene (CGMMV-CP), and successfully transformed a watermelon rootstock named 'gongdae'. The transformation rate was as low as 0.1-0.3%, depending on the transformation method used (ordinary co-culture vs injection, respectively). However, watermelon transformation was reproducibly and reliably achieved using these two methods. Southern blot analysis confirmed that the CGMMV-CP gene was inserted into different locations in the genome either singly or multiple copies. Resistance testing against CGMMV showed that 10 plants among 140 T1 plants were resistant to CGMMV infection. This is the first report of the development by genetic engineering of watermelons resistant to CGMMV infection. |
2,336,808 | History of genetic disease: the molecular genetics of Huntington disease - a history. | The Huntington disease gene was mapped to human chromosome 4p in 1983 and 10 years later the pathogenic mutation was identified as a CAG-repeat expansion. Our current understanding of the molecular pathogenesis of Huntington disease could never have been achieved without the recent progress in the field of molecular genetics. We are now equipped with powerful genetic models that continue to uncover new aspects of the pathogenesis of Huntington disease and will be instrumental for the development of therapeutic approaches for this disease. |
2,336,809 | An autosomal dominant ataxia maps to 19q13: Allelic heterogeneity of SCA13 or novel locus? | The autosomal dominant spinocerebellar ataxias (ADCAs) represent a growing and heterogeneous disease phenotype. Clinical characterization of a three-generation Filipino family segregating a dominant ataxia revealed cerebellar signs and symptoms. After elimination of known spinocerebellar ataxia (SCA) loci, a genome-wide linkage scan revealed a disease locus in a 4-cM region of 19q13, with a 3.89 lod score. This region overlaps and reduces the SCA13 locus. However, this ADCA is clinically distinguishable from SCA13. |
2,336,810 | Initial licking responses of mice to sweeteners: effects of tas1r3 polymorphisms. | Recent studies have established that the T1R3 receptor plays a central role in the taste-mediated ingestive response to sweeteners by mice. First, transgenic mice lacking the gene for T1R3, Tas1r3, show dramatically reduced lick responsiveness to most sweeteners. Second, strains with the taster allele of Tas1r3 (T strains) are more sensitive to low sweetener concentrations than strains with the nontaster allele (NT strains) and consume greater quantities of low- to midrange concentrations of sweeteners during 24-h tests. We asked how Tas1r3 polymorphisms influence the initial licking responses of four T strains (FVB/NJ, SWR/J, SM/J, and C57BL/6J) and four NT strains (BALB/cJ, 129P3/J, DBA/2J, and C3H/HeJ) to two sweeteners (sucrose and SC-45647, an artificial sweetener). We used the initial licking response as a measure of the taste-mediated ingestive response because its brief duration minimizes the potential contribution of nontaste factors (e.g., negative and positive postingestive feedback). Further, we used two complimentary short-term intake tests (the brief-access taste test and a novel 1-min preference test) to reduce the possibility that our findings were an epiphenomenon of a specific testing procedure. In both tests, the T strains were more responsive than the NT strains to low concentrations of each sweetener. At higher concentrations, however, there was considerable overlap between the T and NT strains. In fact, the initial licking response of several NT strains was more vigorous than (or equivalent to) that of several T strains. There was also considerable variation among strains with the same Tas1r3 allele. We conclude that Tas1r3 polymorphisms contribute to strain differences in initial lick responsiveness to low but not high concentrations of sweeteners. |
2,336,811 | Evaluation of candidate genes in the absence of positional information: a poor bet on a blind dog! | More than 350 inherited diseases have been reported in dogs and at least 50% of them have human counterparts. To remove the diseases from dog breeds and to identify canine models for human diseases, it is necessary to find the mutations underlying them. To this end, two methods have been used: the functional candidate gene approach and linkage analysis. Here we present an evaluation of these in canine retinal diseases, which have been the subject of a large number of molecular genetic studies, and we show the contrasting outcomes of these approaches when dealing with genetically heterogeneous diseases. The candidate gene approach has led to 377 published results with 23 genes. Most of the results (66.6%) excluded the presence of a mutation in a gene or its coding region, while only 3.4% of the results identified the mutation causing the disease. On the other hand, five linkage analysis studies have been done on retinal diseases, resulting in three identified mutations and two mapped disease loci. Mapping studies have relied on dog research colonies. If this favorable application of linkage analysis can be extended to dogs in the pet population, success in identifying canine mutations could increase, with advantages to veterinary and human medicine. |
2,336,812 | Atlas: a java-based tool for managing genotypes. | With the exponential increase in genotyping capability, it is fundamental to check data consistency and improve genotype management. Atlas is a Java-based application for managing genotypes that also provides a series of tools useful in traceability, parentage testing, and identification, as well as pedigree and marker visualization. |
2,336,813 | [Genetic polymorphism of FIBRA,DHFRP2 and ACTBP2 and their forensic application in Yunnan Han population]. | To investigate the genetic polymorphism of FIBRA,DHFRP2 and ACTBP2 in Yunnan Han population as well as their application in forensic science, EDTA-blood specimens were collected from 200 healthy individuals. The DNA were extracted either by the Chloro form, phenol method or by the Chelex-100 method. The PCR products were analyzed by PAG vertical electrophoresis,following by silver staining. All gene frequencies, discrimination power (DP), exclusion of paternity probability (EPP), heterozygosity (H),polymorphisms information content (PIC),matching probability (PM) as well as the Hardy-Weinberg test were calculated. The obtained data are beneficial in the understanding of population genetics of the three STR loci in Yunnan Han population and the results suggest that these loci are valuable genetic markers for paternity testing and personal identification in forensic science practice. |
2,336,814 | Association study of mast cell chymase polymorphisms with atopy. | Atopic disorders are the result of complex interactions between genetic and environmental factors. Associations analyses between the promoter polymorphism rs1800875 in the mast cell chymase gene (CMA1) and atopy-related phenotypes have yielded inconsistent results.</AbstractText>We sequenced the CMA1 locus in 24 unrelated healthy individuals with serum IgE levels <50% percentile and 24 individuals with atopic eczema and serum IgE levels >90% percentile. Seven CMA1 single nucleotide polymorphisms (SNPs) were evaluated for evidence of associations with atopic phenotypes within a large population of German adults (n = 1875). Subjects were phenotyped by standardized questionnaires and interviews, skin prick testing and serum IgE measurements. Genotyping was performed using MALDI-TOF MS (Matrix-Assisted Laser Desorption Ionization-Time of Flight mass spectrometry).</AbstractText>Promoter polymorphism rs1800875 was significantly associated with atopic eczema. No associations between any other single SNP and atopic phenotypes could be detected. Haplotype reconstruction revealed four of 128 possible haplotypes reaching estimated frequencies of 3% or more. Two of these haplotypes showed a borderline-significant association with atopic eczema, which did not remain significant after correction for multiple testing.</AbstractText>Results confirm previous observations of a significant association between the CMA1 promoter polymorphism rs1800875 and atopic eczema, but not with serum IgE levels, and support the hypothesis that CMA1 serves as candidate gene for atopic eczema.</AbstractText> |
2,336,815 | [Chromosome STR genetic markers in paternity identification]. | To explore the application of paternity identification by chromosome STR genetic markers (short tandem repeat).</AbstractText>The paternity testings in 468 cases were routinely carried out using amphibian STR Profiler plus and Cofiler PCR amplification kits. When STR exclusions were found, HLA system and other blood groups were detected by molecular typing and loci of PowerPlex 16 system. STR loci were genotyped. If necessary, the genotyping of Y chromosome specific STR, X chromosome specific STR and HLA allelic sequencing were added.</AbstractText>W of 408 cases of paternity was more than 0.95, and that of 350 cases was more than 0. 9995. W of 60 cases of unrelated individuals was less than 0.8, and that of another 48 cases was less than 0.27. By Chi-Square test, there was significant difference (P < 0.001) in the entire-same allelic genes and the entire-different allelic genes and no significant difference (P > 0.05) in the half-same between allelic genes the two groups.</AbstractText>It is effective to identify the paternity by STR genetic markers. The pair is related when the locus number of entirely-different allelic genes is less than 1 or that of the entirely-same allelic genes is more than 6.</AbstractText> |
2,336,816 | Relative values. | As knowlege about the links between genes and cancer expands, those at risk need proper assessment and reliable information. Nurses on Teesside are providing both. |
2,336,817 | Evolutionary conservation of bacterial operons: does transcriptional connectivity matter? | In the literature, it has been frequently suggested that the connectivity of a protein, i.e., the number of proteins with which it interacts, is inversely correlated with the rate of evolution. We attempted to extrapolate from proteins to operons by testing the hypothesis that operons with high transcriptional connectivity, i.e., operons that are controlled through interactions with many transcription factors, are evolutionarily more conserved at the structure and sequence levels than low-connectivity operons. With Escherichia coli used as reference, two structural- and two sequence-conservation measures were determined for 82 groups of homologous operons from 30 completely-sequenced bacterial genomes. In E. coli, large operons tend to be regulated by more transcription factors than either smaller operons or single genes. Large E. coli operons that are regulated by single transcription factors were found to be regulated by activators more frequently than by repressors. Levels of sequence conservation and structural conservation of operons were found to be independent of each other, i.e., structurally conserved operons may be divergent in sequence, and vice versa. Transcriptional connectivity was found to influence neither sequence nor structural conservation of operons. Although this finding seems to contradict the situation in genes, a critical review of the literature indicates that although gene connectivity is frequently touted as a factor in determining rates of evolution, only a very small fraction of the variability in degrees of evolutionary conservation is explainable by this factor. |
2,336,818 | Understanding and treating neurodegeneration: insights from the flies. | Drosophila has recently emerged as a model system for studying mechanisms of neurodegeneration. Genetic models for most of the major neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), polyglutamine diseases, and tauopathies, have been successfully established. Pharmacological models of some of these diseases have also been created. Genetic modifier screens using these models have uncovered previously implicated mechanisms and molecules as well as novel ones. Fly models have turned out to be excellent system for the in vivo testing of therapeutic potentials of candidate compounds. It is anticipated that further exploration of the fly models will not only provide novel insights into mechanisms of neurodegeneration but also lead to the development of rational treatment of those debilitating degenerative diseases.</Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Bingwei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pathology, GRECC, VA Palo Alto Health Care System, Stanford University School of Medicine, Palo Alto, CA 94304 USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2005</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Age (Dordr)</MedlineTA><NlmUniqueID>101250497</NlmUniqueID><ISSNLinking>0161-9152</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer's disease</Keyword><Keyword MajorTopicYN="N">Drosophila</Keyword><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">disease modeling</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">polyglutamine disease</Keyword><Keyword MajorTopicYN="N">tauopathy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23598655</ArticleId><ArticleId IdType="pmc">PMC3458495</ArticleId><ArticleId IdType="doi">10.1007/s11357-005-2917-y</ArticleId><ArticleId IdType="pii">22917</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akassoglou K, Malester B, Xu J, Tessarollo L, Rosenbluth J, Chao MV. Brain-specific deletion of neuropathy target esterase/swisscheese results in neurodegeneration. Proc Natl Acad Sci USA. 2004;101:5075–5080. doi: 10.1073/pnas.0401030101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0401030101</ArticleId><ArticleId IdType="pmc">PMC387376</ArticleId><ArticleId IdType="pubmed">15051870</ArticleId></ArticleIdList></Reference><Reference><Citation>Albers DS, Beal MF. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl. 2000;59:133–154.</Citation><ArticleIdList><ArticleId IdType="pubmed">10961426</ArticleId></ArticleIdList></Reference><Reference><Citation>Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (Berl) 2002;103:26–35. doi: 10.1007/s004010100423.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s004010100423</ArticleId><ArticleId IdType="pubmed">11837744</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Bonini NM. Pharmacological prevention of Parkinson disease in Drosophila. Nat Med. 2002;8:1185–1186. doi: 10.1038/nm1102-1185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1102-1185</ArticleId><ArticleId IdType="pubmed">12411925</ArticleId></ArticleIdList></Reference><Reference><Citation>Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science. 2002;295:865–868. doi: 10.1126/science.1067389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1067389</ArticleId><ArticleId IdType="pubmed">11823645</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms H, Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and cdk5. FEBS Lett. 1993;336:417–424. doi: 10.1016/0014-5793(93)80849-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(93)80849-P</ArticleId><ArticleId IdType="pubmed">8282104</ArticleId></ArticleIdList></Reference><Reference><Citation>Beal MF. Experimental models of Parkinson's disease. Nat Rev Neurosci. 2001;2:325–334. doi: 10.1038/35072550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35072550</ArticleId><ArticleId IdType="pubmed">11331916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoli-Avella AM, Oostra BA, Heutink P. Chasing genes in Alzheimer's and Parkinson's disease. Hum Genet. 2004;114:413–438. doi: 10.1007/s00439-004-1097-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-004-1097-7</ArticleId><ArticleId IdType="pubmed">14999561</ArticleId></ArticleIdList></Reference><Reference><Citation>Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays. 2002;24:308–318. doi: 10.1002/bies.10067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.10067</ArticleId><ArticleId IdType="pubmed">11948617</ArticleId></ArticleIdList></Reference><Reference><Citation>Biernat J, Wu YZ, Timm T, Zheng-Fischhofer Q, Mandelkow E, Meijer L, et al. Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell. 2002;13:4013–4028. doi: 10.1091/mbc.02-03-0046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.02-03-0046</ArticleId><ArticleId IdType="pmc">PMC133611</ArticleId><ArticleId IdType="pubmed">12429843</ArticleId></ArticleIdList></Reference><Reference><Citation>Billingsley ML, Kincaid RL. Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J. 1997;323(Pt 3):577–591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1218358</ArticleId><ArticleId IdType="pubmed">9169588</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohm H, Brinkmann V, Drab M, Henske A, Kurzchalia TV. Mammalian homologues of C. elegans PAR-1 are asymmetrically localized in epithelial cells and may influence their polarity. Curr Biol. 1997;7:603–606. doi: 10.1016/S0960-9822(06)00260-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(06)00260-0</ArticleId><ArticleId IdType="pubmed">9259552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, Swieten JC, et al. DJ-1( PARK7), a novel gene for autosomal recessive, early onset Parkinsonism. Neurol Sci. 2003;24:159–160. doi: 10.1007/s10072-003-0108-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-003-0108-0</ArticleId><ArticleId IdType="pubmed">14598065</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonini NM, Fortini ME. Human neurodegenerative disease modeling using Drosophila. Annu Rev Neurosci. 2003;26:627–656. doi: 10.1146/annurev.neuro.26.041002.131425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.26.041002.131425</ArticleId><ArticleId IdType="pubmed">12704223</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239–259. doi: 10.1007/BF00308809.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00308809</ArticleId><ArticleId IdType="pubmed">1759558</ArticleId></ArticleIdList></Reference><Reference><Citation>Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine–sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci USA. 2004;101:9103–9108. doi: 10.1073/pnas.0402959101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402959101</ArticleId><ArticleId IdType="pmc">PMC428480</ArticleId><ArticleId IdType="pubmed">15181200</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan HY, Warrick JM, Andriola I, Merry D, Bonini NM. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Hum Mol Genet. 2002;11:2895–2904. doi: 10.1093/hmg/11.23.2895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/11.23.2895</ArticleId><ArticleId IdType="pubmed">12393801</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HK, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, Fernandez MH, et al. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell. 2003;113:457–468. doi: 10.1016/S0092-8674(03)00349-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(03)00349-0</ArticleId><ArticleId IdType="pubmed">12757707</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleveland DW, Hwo SY, Kirschner MW. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol. 1977;116:207–225. doi: 10.1016/0022-2836(77)90213-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-2836(77)90213-3</ArticleId><ArticleId IdType="pubmed">599557</ArticleId></ArticleIdList></Reference><Reference><Citation>Coulom H, Birman S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J Neurosci. 2004;24:10993–10998. doi: 10.1523/JNEUROSCI.2993-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2993-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730201</ArticleId><ArticleId IdType="pubmed">15574749</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DN, Lu B, Sun TQ, Williams LT, Jan YN. Drosophila par-1 is required for oocyte differentiation and microtubule organization. Curr Biol. 2001;11:75–87. doi: 10.1016/S0960-9822(01)00027-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(01)00027-6</ArticleId><ArticleId IdType="pubmed">11231123</ArticleId></ArticleIdList></Reference><Reference><Citation>Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, Ciechanover A, et al. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron. 1999;24:879–892. doi: 10.1016/S0896-6273(00)81035-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)81035-1</ArticleId><ArticleId IdType="pubmed">10624951</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies P. A very incomplete comprehensive theory of Alzheimer's disease. Ann NY Acad Sci. 2000;924:8–16. doi: 10.1111/j.1749-6632.2000.tb05553.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2000.tb05553.x</ArticleId><ArticleId IdType="pubmed">11193806</ArticleId></ArticleIdList></Reference><Reference><Citation>Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003;302:819–822. doi: 10.1126/science.1087753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1087753</ArticleId><ArticleId IdType="pubmed">14593166</ArticleId></ArticleIdList></Reference><Reference><Citation>Strooper B. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron. 2003;38:9–12. doi: 10.1016/S0896-6273(03)00205-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00205-8</ArticleId><ArticleId IdType="pubmed">12691659</ArticleId></ArticleIdList></Reference><Reference><Citation>Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol. 1994;35:38–44. doi: 10.1002/ana.410350107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410350107</ArticleId><ArticleId IdType="pubmed">8285590</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Z, Wolfer DP, Lipp HP, Bueler H. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol Ther. 2005;11:80–88. doi: 10.1016/j.ymthe.2004.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2004.09.007</ArticleId><ArticleId IdType="pubmed">15585408</ArticleId></ArticleIdList></Reference><Reference><Citation>Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell. 1997;89:297–308. doi: 10.1016/S0092-8674(00)80208-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80208-1</ArticleId><ArticleId IdType="pubmed">9108484</ArticleId></ArticleIdList></Reference><Reference><Citation>Driscoll M, Gerstbrein B. Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nat Rev Genet. 2003;4:181–194. doi: 10.1038/nrg1018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrg1018</ArticleId><ArticleId IdType="pubmed">12610523</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunnett SB, Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature. 1999;399:A32–A39. doi: 10.1038/19899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/19899</ArticleId><ArticleId IdType="pubmed">10392578</ArticleId></ArticleIdList></Reference><Reference><Citation>Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, Zoghbi HY, et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron. 2003;38:375–387. doi: 10.1016/S0896-6273(03)00258-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00258-7</ArticleId><ArticleId IdType="pubmed">12741986</ArticleId></ArticleIdList></Reference><Reference><Citation>Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature. 2000;404:394–398. doi: 10.1038/35006074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35006074</ArticleId><ArticleId IdType="pubmed">10746727</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Funez P, Nino-Rosales ML, Gouyon B, She WC, Luchak JM, Martinez P, et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature. 2000;408:101–106. doi: 10.1038/35040584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35040584</ArticleId><ArticleId IdType="pubmed">11081516</ArticleId></ArticleIdList></Reference><Reference><Citation>Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M. A model for studying Alzheimer's Abeta42-induced toxicity in Drosophila melanogaster. Mol Cell Neurosci. 2004;26:365–375. doi: 10.1016/j.mcn.2004.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2004.03.001</ArticleId><ArticleId IdType="pubmed">15234342</ArticleId></ArticleIdList></Reference><Reference><Citation>Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S. Frontotemporal dementia and Parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann Neurol. 1997;41:706–715. doi: 10.1002/ana.410410606.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410410606</ArticleId><ArticleId IdType="pubmed">9189031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh S, Feany MB. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Hum Mol Genet. 2004;13:2011–2018. doi: 10.1093/hmg/ddh214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh214</ArticleId><ArticleId IdType="pubmed">15254017</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8:159–168. doi: 10.1016/0896-6273(92)90117-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0896-6273(92)90117-V</ArticleId><ArticleId IdType="pubmed">1530909</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz J, Chen F, Dorpe J, Nitsch RM. Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science. 2001;293:1491–1495. doi: 10.1126/science.1062097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1062097</ArticleId><ArticleId IdType="pubmed">11520988</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SG, Davies P. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc Natl Acad Sci USA. 1990;87:5827–5831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC54421</ArticleId><ArticleId IdType="pubmed">2116006</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA. 2003;100:4078–4083. doi: 10.1073/pnas.0737556100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0737556100</ArticleId><ArticleId IdType="pmc">PMC153051</ArticleId><ArticleId IdType="pubmed">12642658</ArticleId></ArticleIdList></Reference><Reference><Citation>Greeve I, Kretzschmar D, Tschape JA, Beyn A, Brellinger C, Schweizer M, et al. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J Neurosci. 2004;24:3899–3906. doi: 10.1523/JNEUROSCI.0283-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0283-04.2004</ArticleId><ArticleId IdType="pmc">PMC6729409</ArticleId><ArticleId IdType="pubmed">15102905</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 1986;83:4913–4917.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC323854</ArticleId><ArticleId IdType="pubmed">3088567</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo S, Kemphues KJ. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell. 1995;81:611–620. doi: 10.1016/0092-8674(95)90082-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(95)90082-9</ArticleId><ArticleId IdType="pubmed">7758115</ArticleId></ArticleIdList></Reference><Reference><Citation>Gusella JF, MacDonald ME. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci. 2000;1:109–115. doi: 10.1038/35039051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35039051</ArticleId><ArticleId IdType="pubmed">11252773</ArticleId></ArticleIdList></Reference><Reference><Citation>Haass C, Strooper B. The presenilins in Alzheimer's disease-proteolysis holds the key. Science. 1999;286:916–919. doi: 10.1126/science.286.5441.916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5441.916</ArticleId><ArticleId IdType="pubmed">10542139</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem. 1998;71:2465–2476.</Citation><ArticleIdList><ArticleId IdType="pubmed">9832145</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353–356. doi: 10.1126/science.1072994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1072994</ArticleId><ArticleId IdType="pubmed">12130773</ArticleId></ArticleIdList></Reference><Reference><Citation>Haywood AF, Staveley BE. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci. 2004;5:14. doi: 10.1186/1471-2202-5-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-5-14</ArticleId><ArticleId IdType="pmc">PMC419346</ArticleId><ArticleId IdType="pubmed">15090075</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci. 2003;991:214–228.</Citation><ArticleIdList><ArticleId IdType="pubmed">12846989</ArticleId></ArticleIdList></Reference><Reference><Citation>Hod Y, Pentyala SN, Whyard TC, El-Maghrabi MR. Identification and characterization of a novel protein that regulates RNA–protein interaction. J Cell Biochem. 1999;72:435–444. doi: 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.0.CO;2-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.0.CO;2-H</ArticleId><ArticleId IdType="pubmed">10022524</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou CE, Carlin D, Miller BL. Non-Alzheimer's disease dementias: anatomic, clinical, and molecular correlates. Can J Psychiatry. 2004;49:164–171.</Citation><ArticleIdList><ArticleId IdType="pubmed">15101498</ArticleId></ArticleIdList></Reference><Reference><Citation>Houseley JM, Wang Z, Brock GJ, Soloway J, Artero R, Perez-Alonso M, et al. Myotonic dystrophy associated expanded CUG repeat muscleblind positive ribonuclear foci are not toxic to Drosophila. Hum Mol Genet. 2005;14:873–883. doi: 10.1093/hmg/ddi080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi080</ArticleId><ArticleId IdType="pubmed">15703191</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, et al. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol. 2000;157:401–410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1850140</ArticleId><ArticleId IdType="pubmed">10934145</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, et al. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–705. doi: 10.1038/31508.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/31508</ArticleId><ArticleId IdType="pubmed">9641683</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima K, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y. Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease. Proc Natl Acad Sci USA. 2004;101:6623–6628. doi: 10.1073/pnas.0400895101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0400895101</ArticleId><ArticleId IdType="pmc">PMC404095</ArticleId><ArticleId IdType="pubmed">15069204</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell. 2001;105:891–902. doi: 10.1016/S0092-8674(01)00407-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(01)00407-X</ArticleId><ArticleId IdType="pubmed">11439185</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanowski JQ, et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 1999;24:751–762. doi: 10.1016/S0896-6273(00)81127-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)81127-7</ArticleId><ArticleId IdType="pubmed">10595524</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, Faber PW, et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron. 1998;21:633–642. doi: 10.1016/S0896-6273(00)80573-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(00)80573-5</ArticleId><ArticleId IdType="pubmed">9768849</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 2002;34:509–519. doi: 10.1016/S0896-6273(02)00706-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00706-7</ArticleId><ArticleId IdType="pubmed">12062036</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003;53(Suppl 3):S26–S36. doi: 10.1002/ana.10483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.10483</ArticleId><ArticleId IdType="pubmed">12666096</ArticleId></ArticleIdList></Reference><Reference><Citation>Jicha GA, Weaver C, Lane E, Vianna C, Kress Y, Rockwood J, et al. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer's disease. J Neurosci. 1999;19:7486–7494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782506</ArticleId><ArticleId IdType="pubmed">10460255</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin P, Zarnescu DC, Zhang F, Pearson CE, Lucchesi JC, Moses K, et al. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron. 2003;39:739–747. doi: 10.1016/S0896-6273(03)00533-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00533-6</ArticleId><ArticleId IdType="pubmed">12948442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science. 2000;287:1837–1840. doi: 10.1126/science.287.5459.1837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.287.5459.1837</ArticleId><ArticleId IdType="pubmed">10710314</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinumi T, Kimata J, Taira T, Ariga H, Niki E. Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2004;317:722–728. doi: 10.1016/j.bbrc.2004.03.110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.03.110</ArticleId><ArticleId IdType="pubmed">15081400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile Parkinsonism. Nature. 1998;392:605–608. doi: 10.1038/33416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/33416</ArticleId><ArticleId IdType="pubmed">9560156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kretzschmar D, Hasan G, Sharma S, Heisenberg M, Benzer S. The swiss cheese mutant causes glial hyperwrapping and brain degeneration in Drosophila. J Neurosci. 1997;17:7425–7432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6573436</ArticleId><ArticleId IdType="pubmed">9295388</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis GN, Abdueva D, Skvortsov D, Yang J, Rabin BE, Carrick J, et al. Similar gene expression patterns characterize aging and oxidative stress in Drosophila melanogaster. Proc Natl Acad Sci USA. 2004;101:7663–7668. doi: 10.1073/pnas.0307605101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0307605101</ArticleId><ArticleId IdType="pmc">PMC419663</ArticleId><ArticleId IdType="pubmed">15136717</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee VM, Balin BJ, Otvos L, Jr, Trojanowski JQ. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science. 1991;251:675–678.</Citation><ArticleIdList><ArticleId IdType="pubmed">1899488</ArticleId></ArticleIdList></Reference><Reference><Citation>Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998;395:451–452. doi: 10.1038/26652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/26652</ArticleId><ArticleId IdType="pubmed">9774100</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Slegtenhorst M, et al. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet. 2000;25:402–405. doi: 10.1038/78078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/78078</ArticleId><ArticleId IdType="pubmed">10932182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science. 2001;293:1487–1491. doi: 10.1126/science.1058189.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1058189</ArticleId><ArticleId IdType="pubmed">11520987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T, et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci USA. 2004;101:17510–17515. doi: 10.1073/pnas.0405313101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0405313101</ArticleId><ArticleId IdType="pmc">PMC536019</ArticleId><ArticleId IdType="pubmed">15576511</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol. 1998;8:425–427. doi: 10.1016/S0962-8924(98)01368-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0962-8924(98)01368-3</ArticleId><ArticleId IdType="pubmed">9854307</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandelkow EM, Drewes G, Biernat J, Gustke N, Lint J, Vandenheede JR, et al. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. FEBS Lett. 1992;314:315–321. doi: 10.1016/0014-5793(92)81496-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(92)81496-9</ArticleId><ArticleId IdType="pubmed">1334849</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, Purcell J, et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet. 2000;9:13–25. doi: 10.1093/hmg/9.1.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/9.1.13</ArticleId><ArticleId IdType="pubmed">10587574</ArticleId></ArticleIdList></Reference><Reference><Citation>Min KT, Benzer S. Preventing neurodegeneration in the Drosophila mutant bubblegum. Science. 1999;284:1985–1988. doi: 10.1126/science.284.5422.1985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.284.5422.1985</ArticleId><ArticleId IdType="pubmed">10373116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto A, Nakagawa Y. DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res. 2001;35:885–893.</Citation><ArticleIdList><ArticleId IdType="pubmed">11811539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto A, Nakagawa Y, Takeuchi A, Okawa K, Iwamatsu A, Takanezawa Y. Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic Res. 2001;35:301–310.</Citation><ArticleIdList><ArticleId IdType="pubmed">11697128</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, Squire A, et al. GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry. 2004;9:522–530. doi: 10.1038/sj.mp.4001483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.mp.4001483</ArticleId><ArticleId IdType="pubmed">14993907</ArticleId></ArticleIdList></Reference><Reference><Citation>Muqit MM, Feany MB. Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat Rev Neurosci. 2002;3:237–243. doi: 10.1038/nrn751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn751</ArticleId><ArticleId IdType="pubmed">11994755</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutsuddi M, Marshall CM, Benzow KA, Koob MD, Rebay I. The spinocerebellar ataxia 8 noncoding RNA causes neurodegeneration and associates with staufen in Drosophila. Curr Biol. 2004;14:302–308. doi: 10.1016/S0960-9822(04)00048-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0960-9822(04)00048-X</ArticleId><ArticleId IdType="pubmed">14972680</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai Y, Fujikake N, Ohno K, Higashiyama H, Popiel HA, Rahadian J, et al. Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. Hum Mol Genet. 2003;12:1253–1259. doi: 10.1093/hmg/ddg144.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg144</ArticleId><ArticleId IdType="pubmed">12761040</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun. 1997;231:509–513. doi: 10.1006/bbrc.1997.6132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1997.6132</ArticleId><ArticleId IdType="pubmed">9070310</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura I, Yang Y, Lu B. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell. 2004;116:671–682. doi: 10.1016/S0092-8674(04)00170-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(04)00170-9</ArticleId><ArticleId IdType="pubmed">15006350</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron. 2003;39:409–421. doi: 10.1016/S0896-6273(03)00434-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00434-3</ArticleId><ArticleId IdType="pubmed">12895417</ArticleId></ArticleIdList></Reference><Reference><Citation>Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron. 2004;43:321–332. doi: 10.1016/j.neuron.2004.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.07.003</ArticleId><ArticleId IdType="pubmed">15294141</ArticleId></ArticleIdList></Reference><Reference><Citation>Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595–600. doi: 10.1016/j.neuron.2004.10.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.10.023</ArticleId><ArticleId IdType="pubmed">15541308</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Klose J, et al. Mitochondrial dysfunction and oxidative damage in Parkin-deficient mice. J Biol Chem. 2004;279:18614–18622. doi: 10.1074/jbc.M401135200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M401135200</ArticleId><ArticleId IdType="pubmed">14985362</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, Zhou Y, et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development. 2004;131:2183–2194. doi: 10.1242/dev.01095.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/dev.01095</ArticleId><ArticleId IdType="pubmed">15073152</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: Proteasome dysfunction selectively affects catecholaminergic neurons. Neuron. 2002;36:1007–1019. doi: 10.1016/S0896-6273(02)01125-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)01125-X</ArticleId><ArticleId IdType="pubmed">12495618</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollitt SK, Pallos J, Shao J, Desai UA, Ma AA, Thompson LM, et al. A rapid cellular FRET assay of polyglutamine aggregation identifies a novel inhibitor. Neuron. 2003;40:685–694. doi: 10.1016/S0896-6273(03)00697-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00697-4</ArticleId><ArticleId IdType="pubmed">14622574</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045–2047. doi: 10.1126/science.276.5321.2045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.276.5321.2045</ArticleId><ArticleId IdType="pubmed">9197268</ArticleId></ArticleIdList></Reference><Reference><Citation>Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Anderson L, et al. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815–825. doi: 10.1002/ana.410430617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410430617</ArticleId><ArticleId IdType="pubmed">9629852</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissman RA, Poon WW, Blurton-Jones M, Oddo S, Torp R, Vitek MP, et al. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest. 2004;114:121–130. doi: 10.1172/JCI200420640.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI200420640</ArticleId><ArticleId IdType="pmc">PMC437967</ArticleId><ArticleId IdType="pubmed">15232619</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogina B, Benzer S, Helfand SL. Drosophila drop-dead mutations accelerate the time course of age-related markers. Proc Natl Acad Sci USA. 1997;94:6303–6306. doi: 10.1073/pnas.94.12.6303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.12.6303</ArticleId><ArticleId IdType="pmc">PMC21044</ArticleId><ArticleId IdType="pubmed">9177212</ArticleId></ArticleIdList></Reference><Reference><Citation>Sang TK, Li C, Liu W, Rodriguez A, Abrams JM, Zipursky SL, et al. Inactivation of Drosophila Apaf-1 related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. Hum Mol Genet. 2005;14:357–372. doi: 10.1093/hmg/ddi032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddi032</ArticleId><ArticleId IdType="pubmed">15590702</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherzer CR, Jensen RV, Gullans SR, Feany MB. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. Hum Mol Genet. 2003;12:2457–2466. doi: 10.1093/hmg/ddg265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddg265</ArticleId><ArticleId IdType="pubmed">12915459</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen J, Cookson MR. Mitochondria and dopamine; new insights into recessive Parkinsonism. Neuron. 2004;43:301–304. doi: 10.1016/j.neuron.2004.07.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.07.012</ArticleId><ArticleId IdType="pubmed">15294138</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherer TB, Betarbet R, Stout AK, Lund S, Baptista M, Panov AV, et al. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J Neurosci. 2002;22:7006–7015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6757862</ArticleId><ArticleId IdType="pubmed">12177198</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, et al. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease. Science. 2001;293:263–269. doi: 10.1126/science.1060627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1060627</ArticleId><ArticleId IdType="pubmed">11431533</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, Feany MB. Genetic modifiers of tauopathy in Drosophila. Genetics. 2003;165:1233–1242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1462852</ArticleId><ArticleId IdType="pubmed">14668378</ArticleId></ArticleIdList></Reference><Reference><Citation>Shulman JM, Benton R, St Johnston D. The Drosophila homolog of C elegans PAR-1 organizes the oocyte cytoskeleton and directs oskar mRNA localization to the posterior pole. Cell. 2000;101:377–388. doi: 10.1016/S0092-8674(00)80848-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80848-X</ArticleId><ArticleId IdType="pubmed">10830165</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh TJ, Wang JZ, Novak M, Kontzekova E, Grundke-Iqbal I, Iqbal K. Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules. FEBS Lett. 1996;387:145–148. doi: 10.1016/0014-5793(96)00485-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(96)00485-1</ArticleId><ArticleId IdType="pubmed">8674537</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohal RS. Role of oxidative stress and protein oxidation in the aging process. Free Radic Biol Med. 2002;33:37–44. doi: 10.1016/S0891-5849(02)00856-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5849(02)00856-0</ArticleId><ArticleId IdType="pubmed">12086680</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci USA. 1998;95:7737–7741. doi: 10.1073/pnas.95.13.7737.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.13.7737</ArticleId><ArticleId IdType="pmc">PMC22742</ArticleId><ArticleId IdType="pubmed">9636220</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001;413:739–743. doi: 10.1038/35099568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35099568</ArticleId><ArticleId IdType="pubmed">11607033</ArticleId></ArticleIdList></Reference><Reference><Citation>Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, Slepko N, et al. SUMO modification of Huntingtin and Huntington's disease pathology. Science. 2004;304:100–104. doi: 10.1126/science.1092194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1092194</ArticleId><ArticleId IdType="pubmed">15064418</ArticleId></ArticleIdList></Reference><Reference><Citation>Struhl G, Greenwald I. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature. 1999;398:522–525. doi: 10.1038/19091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/19091</ArticleId><ArticleId IdType="pubmed">10206646</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun TQ, Lu B, Feng JJ, Reinhard C, Jan YN, Fantl WJ, et al. PAR-1 is a Dishevelled-associated kinase and a positive regulator of Wnt signalling. Nat Cell Biol. 2001;3:628–636. doi: 10.1038/35083016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35083016</ArticleId><ArticleId IdType="pubmed">11433294</ArticleId></ArticleIdList></Reference><Reference><Citation>Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 2004;5:213–218. doi: 10.1038/sj.embor.7400074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.embor.7400074</ArticleId><ArticleId IdType="pmc">PMC1298985</ArticleId><ArticleId IdType="pubmed">14749723</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K, Taira T, Niki T, Seino C, Iguchi-Ariga SM, Ariga H. DJ-1 positively regulates the androgen receptor by impairing the binding of PIASx alpha to the receptor. J Biol Chem. 2001;276:37556–37563. doi: 10.1074/jbc.M101730200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M101730200</ArticleId><ArticleId IdType="pubmed">11477070</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi-Niki K, Niki T, Taira T, Iguchi-Ariga SM, Ariga H. Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. Biochem Biophys Res Commun. 2004;320:389–397. doi: 10.1016/j.bbrc.2004.05.187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2004.05.187</ArticleId><ArticleId IdType="pubmed">15219840</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanuka H, et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron. 2002;35:855–864. doi: 10.1016/S0896-6273(02)00875-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00875-9</ArticleId><ArticleId IdType="pubmed">12372281</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomancak P, Piano F, Riechmann V, Gunsalus KC, Kemphues KJ, Ephrussi A. A Drosophila melanogaster homologue of Caenorhabditis elegans par-1 acts at an early step in embryonic-axis formation. Nat Cell Biol. 2000;2:458–460. doi: 10.1038/35017101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/35017101</ArticleId><ArticleId IdType="pubmed">10878812</ArticleId></ArticleIdList></Reference><Reference><Citation>Unoki M, Nakamura Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene. 2001;20:4457–4465. doi: 10.1038/sj.onc.1204608.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.onc.1204608</ArticleId><ArticleId IdType="pubmed">11494141</ArticleId></ArticleIdList></Reference><Reference><Citation>Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304:1158–1160. doi: 10.1126/science.1096284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1096284</ArticleId><ArticleId IdType="pubmed">15087508</ArticleId></ArticleIdList></Reference><Reference><Citation>Warrick JM, Paulson HL, Gray-Board GL, Bui QT, Fischbeck KH, Pittman RN, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell. 1998;93:939–949. doi: 10.1016/S0092-8674(00)81200-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)81200-3</ArticleId><ArticleId IdType="pubmed">9635424</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams DW, Tyrer M, Shepherd D. Tau and tau reporters disrupt central projections of sensory neurons in Drosophila. J Comp Neurol. 2000;428:630–640. doi: 10.1002/1096-9861(20001225)428:4<630::AID-CNE4>3.0.CO;2-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1096-9861(20001225)428:4<630::AID-CNE4>3.0.CO;2-X</ArticleId><ArticleId IdType="pubmed">11077417</ArticleId></ArticleIdList></Reference><Reference><Citation>Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711–714. doi: 10.1126/science.1062382.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1062382</ArticleId><ArticleId IdType="pubmed">11408621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu YR, Wang CK, Chen CM, Hsu Y, Lin SJ, Lin YY, et al. Analysis of heat-shock protein 70 gene polymorphisms and the risk of Parkinson's disease. Hum Genet. 2004;114:236–241. doi: 10.1007/s00439-003-1050-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00439-003-1050-1</ArticleId><ArticleId IdType="pubmed">14605873</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease—A double-edged sword. Neuron. 2002;35:419–432. doi: 10.1016/S0896-6273(02)00794-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(02)00794-8</ArticleId><ArticleId IdType="pubmed">12165466</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron. 2003;37:911–924. doi: 10.1016/S0896-6273(03)00143-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(03)00143-0</ArticleId><ArticleId IdType="pubmed">12670421</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye Y, Lukinova N, Fortini ME. Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants. Nature. 1999;398:525–529. doi: 10.1038/19096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/19096</ArticleId><ArticleId IdType="pubmed">10206647</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota T, Sugawara K, Ito K, Takahashi R, Ariga H, Mizusawa H. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun. 2003;312:1342–1348. doi: 10.1016/j.bbrc.2003.11.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2003.11.056</ArticleId><ArticleId IdType="pubmed">14652021</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Dawson VL, Dawson TM. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis. 2000;7:240–250. doi: 10.1006/nbdi.2000.0319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2000.0319</ArticleId><ArticleId IdType="pubmed">10964596</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci USA. 2005;102:892–897. doi: 10.1073/pnas.0408936102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0408936102</ArticleId><ArticleId IdType="pmc">PMC545525</ArticleId><ArticleId IdType="pubmed">15642944</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant Parkinsonism with pleomorphic pathology. Neuron. 2004;44:601–607. doi: 10.1016/j.neuron.2004.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.11.005</ArticleId><ArticleId IdType="pubmed">15541309</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou S, Meadows S, Sharp L, Jan LY, Jan YN. Genome-wide study of aging and oxidative stress response in Drosophila melanogaster. Proc Natl Acad Sci USA. 2000;97:13726–13731. doi: 10.1073/pnas.260496697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.260496697</ArticleId><ArticleId IdType="pmc">PMC17643</ArticleId><ArticleId IdType="pubmed">11095759</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedBookArticle><BookDocument><PMID Version="1">20722133</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK43308</ArticleId></ArticleIdList><Book><Publisher><PublisherName>Agency for Healthcare Research and Quality (US)</PublisherName><PublisherLocation>Rockville (MD)</PublisherLocation></Publisher><BookTitle book="es37">Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility</BookTitle><PubDate><Year>2005</Year><Month>09</Month></PubDate><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Heidi D</ForeName><Initials>HD</Initials><AffiliationInfo><Affiliation>Oregon Evidence-based Practice Center, Portland, OR</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huffman</LastName><ForeName>Laurie Hoyt</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Oregon Evidence-based Practice Center, Portland, OR</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Rongwei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Oregon Evidence-based Practice Center, Portland, OR</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Emily L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Oregon Evidence-based Practice Center, Portland, OR</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Miranda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Oregon Evidence-based Practice Center, Portland, OR</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bougatsos</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Oregon Evidence-based Practice Center, Portland, OR</Affiliation></AffiliationInfo></Author></AuthorList><CollectionTitle book="hsevidsyncollect">U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews</CollectionTitle><Medium>Internet</Medium></Book><Language>eng</Language><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText Label="CONTEXT">Breast cancer is the second most common cancer in women in the U.S. and is the second leading cause of cancer death. Although less common, ovarian cancer is associated with high morbidity and mortality. Both breast and ovarian cancer are associated with a family history of these conditions and, in some families, the pattern of cancers suggests the presence of a dominantly inherited cancer susceptibility gene. Two genes, <i>BRCA1</i> and <i>BRCA2</i>, have been identified as breast cancer susceptibility genes, and clinically significant mutations are estimated to occur in about 1 in 300 to 500 of the general population.<AbstractText Label="OBJECTIVE">Screening for inherited breast and ovarian cancer susceptibility is a two-step process that includes an assessment of risk for clinically significant <i>BRCA</i> mutations followed by genetic testing of high-risk individuals. The evidence synthesis describes the strengths and limits of evidence about the effectiveness of selecting, testing, and managing patients in the course of screening in the primary care setting. Its objective is to determine the balance of benefits and adverse effects of screening based on available evidence. The target population includes adult women without preexisting breast or ovarian cancer presenting for routine care in the U.S.<AbstractText Label="DATA SOURCES">Relevant studies were identified from multiple searches of MEDLINE® (1966 to October 1, 2004), Cochrane Library databases, reference lists of pertinent studies, reviews, editorials, and websites, and by consulting experts.<AbstractText Label="STUDY SELECTION">Investigators reviewed all abstracts identified by the searches and determined eligibility by applying inclusion and exclusion criteria specific to key questions about risk assessment, mutation testing, prevention interventions, and potential adverse effects including ethical, legal, and social implications (ELSI). Eligible studies had English-language abstracts, were applicable to U.S. clinical practice, and provided primary data relevant to key questions.<AbstractText Label="DATA EXTRACTION">All eligible studies were reviewed and data were extracted from each study, entered into evidence tables, and summarized by descriptive and statistical methods as appropriate. Two reviewers independently rated the quality of studies using USPSTF criteria.<AbstractText Label="DATA SYNTHESIS">A primary care approach to screening for <i>BRCA</i> genetic susceptibility for breast and ovarian cancer has not been tested. No studies directly evaluated whether screening by risk assessment and <i>BRCA</i> mutation testing leads to a reduction in the incidence of breast and ovarian cancer and cause-specific and/or all cause mortality. Assessment tools that estimate the risk of clinically significant <i>BRCA</i> mutations are available to clinicians, but have not been widely evaluated in primary care settings. Several referral guidelines have been developed for primary care, but there is no consensus or gold standard for use. Trials reported that genetic counseling may increase accuracy of risk perception, and decrease breast cancer worry and anxiety. Estimates of breast and ovarian cancer occurrence, based on studies of <i>BRCA</i> mutation prevalence and penetrance, can be stratified by family history risk groups that are applicable to screening. However, studies are heterogeneous and estimates based on them may not be reliable. Studies of potential adverse effects of risk assessment, genetic counseling, and testing reported decreased rather than increased distress. A meta-analysis of chemoprevention trials in women with unknown mutation status indicated statistically significant effects of selective estrogen receptor modulators in preventing breast cancer and estrogen receptor positive breast cancer, and significantly increased risks for thromboembolic events and endometrial cancer. Observational studies of prophylactic mastectomy and oophorectomy indicated reduced risks of breast and ovarian cancer in <i>BRCA</i> mutation carriers. Studies of patient satisfaction with surgery had mixed results; cancer distress improved, but self-esteem, body image, and other outcomes were adversely affected in some women. Applying this evidence to an outcomes table indicated that the numbers needed to screen to prevent one case of breast (4,000–13,000) or ovarian cancer (7,000) are high among women with an average risk of having a clinically significant <i>BRCA</i> mutation, and decrease as risk increases. Adverse effects also increase as more women are subjected to prevention therapies.<AbstractText Label="CONCLUSIONS">The evidence base for genetic risk assessment and <i>BRCA</i> mutation testing for breast and ovarian cancer susceptibility as a screening strategy is limited by lack of studies demonstrating effectiveness, biases inherent in studies conducted in highly selected populations, and incomplete information on adverse effects.<AbstractText Label="KEYWORDS">Genetic risk assessment, genetic testing, <i>BRCA1</i> and <i>BRCA2</i> mutations, breast cancer, ovarian cancer. |
2,336,819 | Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. | Cystic fibrosis (CF) is a recessive disease caused by mutations of the CF transmembrane conductance regulator (CFTR) gene. The risk of idiopathic chronic pancreatitis (ICP) is increased in individuals who have CFTR genotypes containing a CF-causing mutation plus a second pathogenic allele. It is unknown whether the risk of ICP is increased in CF carriers who have one CF-causing mutation plus one normal allele. In this study, 52 sporadic cases of ICP were ascertained through the European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer. Individuals with pathogenic cationic trypsinogen mutations were excluded. DNA was comprehensively tested for CFTR mutations using a robotically enhanced, multiplexed, and highly redundant form of single-strand conformation polymorphism (SSCP) analysis followed by DNA sequencing. Fifteen subjects had a total of 18 pathogenic CFTR alleles. Eight subjects had common CF-causing mutations. This group included seven CF carriers in whom the second CFTR allele was normal (4.3 times the expected frequency, P=0.0002). Three subjects had compound heterozygotes genotypes containing two pathogenic alleles (31 times the expected frequency, P<0.0001). A variant allele of uncertain significance (p.R75Q) was detected in eight of the 52 ICP subjects and at a similar frequency (13/96) in random donors. ICP differs from other established CFTR-related conditions in that ICP risk is increased in CF carriers who have one documented normal CFTR allele. Having two CFTR mutations imparts a higher relative risk, while having only one mutation imparts a higher attributable risk. |
2,336,820 | Mannose binding lectin acute phase activity in patients with severe infection. | Mannose Binding Lectin (MBL) is a liver derived, circulating plasma protein that plays a pivotal role in innate immunity. MBL functions as a pathogen recognition molecule, opsonising organisms and initiating the complement cascade. MBL deficiency arising from mutations and promoter polymorphisms in the MBL2 gene is common and has been associated with risk, severity, and frequency of infection in a number of clinical settings. With MBL therapy on the horizon, the usefulness of replacement MBL therapy has been challenged by the notion, that as an acute phase protein, MBL levels may rise under stress to sufficient levels, in individuals who are usually deficient. This report demonstrates that in patients with sepsis and septic shock, the majority of patients do not display an MBL acute phase response: 41.4% of individuals maintained consistent MBL levels throughout hospital stay, 31.3% of individuals demonstrated a positive acute phase response, and a negative acute phase response was observed in 27.3% of individuals studied. Importantly, a positive acute phase response was generally observed in individuals with wild-type MBL2 genes. When a positive acute phase response was observed in individuals with coding mutation, these individuals demonstrated a normal MBL level on admission to hospital. Furthermore, no individual, regardless of genotype who was MBL deficient at admission was able to demonstrate a positive acute phase response into the normal MBL range. These findings indicate MBL demonstrates a variable acute phase response in the clinical setting of sepsis and septic shock. |
2,336,821 | CARD15/NOD2 is not a predisposing factor for necrotizing enterocolitis. | Multiple factors are incriminated in the etiopathogeny of necrotizing enterocolitis (NEC) in premature infants, including oral feeding, vascular abnormalities, increase in pro-inflammatory cytokines, and inappropriate response of the intestinal barrier to bacterial microflora. CARD15/NOD2 is a gene recently recognized as important in the innate response to gut flora and is involved in Crohn's disease susceptibility. We thus tested its putative role in NEC. Ten children (seven boys and three girls) suffering from NEC who were admitted to Robert Debré hospital between 1999 and 2002 were retrospectively included in the study. Genetic screening of the 11 constant exons and the exon-intron junctions of CARD15/NOD2 by direct sequencing revealed no novel mutations of that gene in NEC patients. Furthermore, the three main mutations of CARD15/NOD2 (R702W, G908R, and 1007fs) associated with susceptibility to Crohn's disease were not found in these patients. Our results suggest that CARD15/NOD2 does not play a major role in genetic susceptibility to NEC. |
2,336,822 | DXS6797 contains two STRs which can be easily haplotyped in both sexes. | DXS6797 is a complex X-chromosomal locus which contains two variable short tandem repeats (STRs) (motif ATCT) separated by 128 non-polymorphic nucleotides. The two STRs can be cleaved apart by Taq I digestion. Conventionally, DXS6797 is typed by measuring the overall amplicon length, providing only eight alleles [polymorphism information content (PIC) 0.733, mean exclusion chance (MEC) 0.712]. Separate amplification would increase the discrimination but obscure the haplotype constellation in females. Therefore, we proceed by amplifying the whole sequence containing both repeats (DXS6797 I and DXS6797 II) using a Fam-labelled forward primer and a Tamra-labelled reverse primer. We then measure the length of the entire double-labelled amplicon and a Taq-I-digested aliquot to infer, for both males and females, compound haplotypes consisting of DXS6797 I and DXS6797 II repeat length. This procedure has the potential to provide 42 DXS6797 haplotypes. If the crossover rate between both STRs is assumed to be <1.5x10(-6), DXS6797 haplotypes could be used for kinship testing like STR alleles. In our German sample (780 X chromosomes), we determined 27 haplotypes (PIC 0.842, MEC 0,834) and in 220 meioses, we found no new mutations. |
2,336,823 | Splicing mutation associated with Rett syndrome and an experimental approach for genetic diagnosis. | Around 80% of Rett syndrome (RS) cases have a mutation or deletion within the coding sequence of the MeCP2 gene. The other RS patients remain genetically undiagnosed. A significant fraction (10-15%) of disease-causing mutations in humans, affect pre-mRNA splicing. Two potential splice mutations were found in the MeCP2 gene in RS patients, however it was not clear whether these mutations in fact interfere with splicing and consequently cause RS. One such mutation is a deletion of the GT dinucleotide at the 5' donor splice site of exon 1 and the other a deletion of the T nucleotide in the polypyrimidine tract (PPT) of intron 3. Here we experimentally assess the effects exerted by these mutations on the expression of MeCP2 in patients' blood samples and on splicing of the MeCP2 transcript using a hybrid minigene in transient transfection experiments. The results revealed that the Delta T mutation in the PPT is a benign polymorphism and that the GT deletion in intron 1 is a bona fide splicing mutation that causes a complete skipping of exon 1 in the minigene transfection experiment. This explains the observed complete elimination of the MeCP2 message and protein in the lymphoblast clones of the RS patient that carry the mutation on the active X. An analysis of the MeCP2 transcript and protein production in lymphoblast clones, as described here, can be used to confirm clinically diagnosed RS patients with no mutation in the MeCP2 coding sequence. This will enable RS diagnosis without specifically identifying a mutation. |
2,336,824 | Coeliac disease diagnosed at Starship Children's Hospital: 1999-2002. | To retrospectively review the clinical presentation and serological testing of children diagnosed with coeliac disease at Starship Children's Hospital (Auckland, New Zealand) over a 4-year period between January 1999 and December 2002.</AbstractText>A review of Starship Hospital medical records of all children diagnosed with coeliac disease by small bowel biopsy between January 1999 and December 2002 was conducted. Patients had anti-gliadin, endomysial, and tissue transglutaminase antibodies performed prior to small bowel biopsy.</AbstractText>There were 48 patients, median age of 6.9 years (range 1.6 to 15.7 years). Comparing symptomatic age groups older and younger than 5 years, the former age group presented significantly more often with abdominal pain (p=0.005) and the latter age group presented significantly more often with failure to thrive (p=0.02). Screening at-risk groups yielded nine children (19%) with asymptomatic disease. Thirty-three of 36 (92%) patients tested positive for the anti-endomysial IgA antibody, and 26 of 27 (96%) patients tested positive with the anti-tissue transglutaminase IgA antibody. Three patients (aged 3, 4, and 6 years of age) were negative for anti-endomysial antibodies (including one also negative for anti-tissue transglutaminase antibody), but all three were positive for anti-gliadin antibody.</AbstractText>Our study found that children with coeliac disease are being diagnosed at an older age. Older children also presented with more abdominal pain while younger children presented with more failure to thrive. At-risk groups for coeliac disease may be asymptomatic and form a significant group of patients diagnosed with coeliac disease. Anti-endomysial and tissue transglutaminase antibodies are reliable tests for coeliac disease. However, in younger patients or if there is a high clinical index of suspicion of coeliac disease, small bowel biopsy should be performed even if the anti-endomysial and tissue transglutaminase antibody tests are negative.</AbstractText> |
2,336,825 | The right to remain in ignorance about genetic information--can such a right be defended in the name of autonomy? | Within the field of medicine, it has become widely accepted that respecting the autonomy of individuals justifies their right to know. More recently, commentators have asked whether such respect also justifies an individual's right not to know; that is, their right to remain in ignorance. In this paper, I examine what the concept of autonomy entails and whether one is justified in exercising a right not to know genetic information about oneself in the name of autonomy. An important distinction is drawn between autonomous choices generally and autonomous choices about how we shall conduct our lives. Against this theoretical discussion, I consider two hypothetical cases. I conclude by claiming that ignorance cannot be justified in the name of autonomy, and furthermore that where genetic information is pertinent to one's future autonomy, one cannot exercise a right not to know. |
2,336,826 | Aldehyde dehydrogenase (ALDH2) activity in hepatoma cells is reduced by an adenoviral vector coding for an ALDH2 antisense mRNA. | Individuals carrying the Glu487Lys coding mutation in the gene for mitochondrial aldehyde dehydrogenase (ALDH2) have a diminished capacity to metabolize acetaldehyde. This deficiency leads to increases in blood acetaldehyde levels when they consume ethanol, which results in an aversion to alcohol and in marked protection against alcoholism. In the present studies, we aimed to mimic the high-acetaldehyde low-ALDH2 activity phenotype in a rat hepatoma cell line by inhibiting Aldh2 gene expression by an Aldh2 antisense-coding gene carried by an adenoviral vector.</AbstractText>We designed and produced elevated titers of adenoviral vectors (10 virions/ml) carrying Aldh2 cDNA cloned in the reverse orientation preceded by a CMV promoter and followed by a poly-A termination signal. Rat hepatoma cells were infected with these vectors.</AbstractText>Studies showed that 1) the antisense gene is actively transcribed in the cells and high levels of antisense mRNA are attained, 2) the antisense gene reduced ALDH2 activity by 65%, and 3) when incubated with 10 mM ethanol, acetaldehyde accumulation by cells increased 8-fold to levels (80-90 microM) known to be aversive to animals and humans.</AbstractText>Data presented show that antialcohol drugs that inhibit Aldh2 gene expression can be generated endogenously in liver cells infected by an adenoviral vector carrying an antisense-coding gene, thus mimicking the high-acetaldehyde phenotype that exists in humans carrying the Glu487Lys mutation who are protected against alcoholism.</AbstractText> |
2,336,827 | Subtelomeric rearrangements in idiopathic mental retardation. | To estimate the frequency of subtelomeric rearrangements in patients with sporadic and non-syndromic idiopathic mental retardation (IMR).</AbstractText>A total of 18 IMR patients were taken for the study. Selection criteria included no known syndromes or chromosomes abnormalities and known causes of IMR. All patients signed an informed consent to participate. Chromosome analysis was carried out on all patients to rule out gross chromosome abnormalities. Lymphocyte cultures were initiated and harvested using standard protocols. For fluorescence in situ hybridization (FISH), Chromoprobe Multiprobe-T system was used. This system consists of 24 embossed areas with each area having one reversibly bound subtelomere probe for a specific chromosome. The subtelomere probes were differentially labeled with green fluorescence for short arm and orange for the long arm. Hybridization, washing and staining are done using standard protocols. A minimum of 5 metaphases were analyzed per chromosome per patient.</AbstractText>A total of 2 subtelomeric rearrangements were detected (11.1%). Case 1 involved a 17-year-old with severe MR, profound deafness and dysmorphic features with reciprocal translocation t(3;7)(q26.2; p15.1). The second case involved a 4.6-year-old with mild developmental delay and a terminal deletion of the long arm of chromosome 2, del(2) (q37.3). The frequency of abnormalities detected in our study is in agreement with published reports.</AbstractText>Subtelomeric screening with FISH is a useful tool for investigation of IMR, however, it is not cost effective in all cases. Conventional chromosome analysis coupled with targeted FISH testing might be the optimal strategy for investigation of IMR.</AbstractText> |
2,336,828 | The new Italian law on assisted reproduction technology (Law 40/2004). | The Italian parliament passed the law on assisted reproduction after a heated debate. The promulgation of this law (Law 40/2004) is the end point of a long and troubled journey that has seen many bills come and go, all of which have failed. The law consists of a whole set of regulations that will have a great impact on health and on society in general. The law is against many of the technical practices of assisted reproduction; several such practices are banned. This paper outlines ethical and medicolegal issues arising in connection with the law. The law states that no more than three embryos must be created at any one time and all the embryos created must be transferred together even if the couple does not need all the embryos. Embryo cryopreservation is also forbidden, as is assisted reproductive technology (ART), which uses a third party in any way, and the screening of embryos for genetic defects. |
2,336,829 | Firing up the nature/nurture controversy: bioethics and genetic determinism. | It is argued here that bioethicists might inadvertently be promoting genetic determinism: the idea that genes alone determine human traits and behaviours. Discussions about genetic testing are used to exemplify how they might be doing so. Quite often bioethicists use clinical cases to support particular moral obligations or rights as if these cases were representative of the kind of information we can acquire about human diseases through genetic testing, when they are not. On other occasions, the clinical cases are presented in simplistic ways that portray genetic testing as yielding information more accurate than it actually is. It is concluded that, because of the problematic implications that the ideology of genetic determinism might have for individuals' wellbeing and for our public policies, bioethicists should be careful to present these issues in ways that do not promote questionable ideas about the causal role of genes in human diseases and behaviours. |
2,336,830 | Noninvasive determination of fetal RHD status by examination of cell-free DNA in maternal plasma. | Cell-free fetal DNA in maternal plasma opens the way for routine risk-free diagnosis of fetal D status of D- mothers. The focus was on accuracy of RHD typing and confirmation of fetal DNA in maternal plasma while RHD was not detected.</AbstractText>Plasma DNA was extracted (by manual and/or automatic method) from 255 D- pregnant women and amplified in exons 7 and 10 and intron 4 of RHD gene with real-time polymerase chain reaction. The presence of fetal DNA was confirmed by testing SRY and, when negative, by one of 11 different polymorphisms found in the father but not in the mother. The results were compared with the D status of the newborns.</AbstractText>After exclusion of 25 cases (10%) because of material shortage, in 230 cases (90%) available for complete study, the predictive value of the procedure of fetal RHD testing (RHD genotyping plus confirmation of fetal DNA) was 99.6 percent. SRY detection confirmed fetal DNA presence in maternal plasma in all boys, whereas the detection of various polymorphisms in all girls but one.</AbstractText>Fetal RHD genotyping from maternal plasma may be used with confidence, although additional polymorphisms for confirmation of fetal DNA should be included for 100 percent predictive value (instead of 99.6%).</AbstractText> |
2,336,831 | Bovine spinal muscular atrophy: AFG3L2 is not a positional candidate gene. | Bovine spinal muscular atrophy (BSMA) is a neurodegenerative disorder, which is widespread in Brown Swiss cattle. Main symptoms of the disease are muscular atrophy and recumbency. Affected calves die within few days or weeks. BSMA seems to be inherited as a recessive trait and the disease allele appears to have a common origin. In this study, a pedigree with 30 affected BSMA calves was used to genetically localize the BSMA locus. Linkage analysis was performed between microsatellite markers of seven chromosomes, where the homologous genes of human neurodegenerative disorders are located according to comparative mapping data, and the disease genotype. BSMA was mapped to chromosome 24 confirming the recently published localization (Medugorac et al. 2003). The candidate gene AFG3L2 was physically mapped to chromosome 24q24 using fluorescence in situ hybridization. Due to their different localizations AFG3L2 is not a positional candidate for BSMA. An informative marker localized on the telomeric side of the BSMA locus would be beneficial for marker-assisted selection as well as searching for the causative gene. However, finding a marker distal to BSMA locus is difficult because of its position at the end of the chromosome. |
2,336,832 | Genome-wide screening for genetic changes in a matched pair of benign and prostate cancer cell lines using array CGH. | Copy number alterations in a matched pair of benign epithelial and prostate cancer cell lines derived from the same patient were assessed using array-based comparative genomic hybridisation (aCGH). The cancer cell line showed a gain of chromosome 7, deletion of chromosome 8, gains (including high level) and losses on chromosome 11, loss of 18p and gain of 20q. Deletions on chromosome 8 were confirmed with microsatellite markers. The aCGH results were compared to gene expression data obtained using DNA microarrays and suggested the involvement of caspases and ICEBERG on 11q and E2F1 on chromosome 20q. |
2,336,833 | Use of Intron 1 and 22 inversions and linkage analysis in carrier detection of hemophilia A in Indians. | Hemophilia A is an X-linked recessively inherited bleeding disorder characterized by deficiency of procoagulant factor VIII (FVIII).</AbstractText>Sixty unrelated hemophilia A patients and their family members have undergone tests for carrier detection by linkage analysis using the polymorphic markers Bcl I, Xba I and Intron 13 or 22 VNTRs. In families of sporadic hemophiliacs, the carrier status of female subjects was ascertained by linkage analysis along with FVIII:C/VWD Ag estimation.</AbstractText>Of the 33 families with positive family history, the defective X chromosome was tracked in 28 mothers. The carrier status of females from hemophilia A families with positive family history, ascertained by linkage analysis and Intron 22 and 1 inversion, was made out in 85% cases. FVIII:C/VWF Ag ratio was evaluated in 36 females from 9 sporadic hemophilic families. Using the FVIII:C/VWF Ag ratio along with linkage analysis, carrier status was determined in 9 (25%) of the 36 females studied. Using Intron 22 inversion along with linkage analysis and FVIII:C/VWF Ag estimation, the informativity in female subjects from families of sporadic hemophiliacs increased from 25% to 52%.</AbstractText>In the West, linkage analysis with Bcl I, Xba I and Intron 13 or 22 VNTR markers and inversion 22 offers a good tool for carrier detection of hemophilia A in India.</AbstractText> |
2,336,834 | Familial non-BRCA1/BRCA2-associated breast cancer. | Multidisciplinary breast-cancer teams commonly encounter women, both premenopausal and postmenopausal, presenting with breast cancer who also have a family history of this disease. Much of the published work on management of hereditary breast cancer focuses on women with known mutations in BRCA1 and BRCA2, in whom high-grade tumours, common second primaries, and a differential response to adjuvant chemotherapies could be relevant in finding the most effective management strategies. Extrapolation of some of these findings to all patients with familial breast cancer is tempting. However, for women in whom BRCA1 or BRCA2 mutations are unlikely or not found, what evidence is there to inform choices about the various management options? We review the published work on management issues for patients with familial breast cancer not due to a detectable mutation in BRCA1/BRCA2 and compare it with the issues for BRCA1 and BRCA2 carriers on whom more information is available. |
2,336,835 | [Recombinant adenovirus mediated hVEGF165 gene transfer promotes recovery of hematopoiesis in post-BMT mice]. | To investigate the effects of vascular endothelial growth factor (VEGF) on the recovery of hematopoiesis in post-BMT mice, the recombinant adenovirus Ad-EGFP/hVEGF(165) was injected into syngeneic BMT BALB/c mice via the tail vein. At day 10, 20, 30 after BMT, the in vivo expression of hVEGF(165) was measured. At the same different time points, the numbers of WBC, Plt, RBC in peripheral blood and MNC in bone marrow were counted. By the way, the bone marrow MNCs at day 30 post-BMT were used for further CFU-S assay. The results indicated that a long-term expression of hVEGF(165) in plasma and different organs was successfully mediated by recombinant adenovirus. At each time point of post-BMT, the numbers of WBC, Plt, RBC as well as bone marrow MNC observed in the group treated with recombinant adenovirus Ad-EGFP/hVEGF(165) were lower than those of the normal control group, but were higher than those in other testing groups (P < 0.05). The number of CFU-S (21.4 +/- 2.67) formed by bone marrow MNC at day 30 after BMT reached to the normal level (19.50 +/- 2.46) (P > 0.05), which was much higher than that in other groups (P < 0.05). It is concluded that hVEGF(165) gene transfer mediated by recombinant adenovirus plays a role of promoting the recovery of hematopoiesis in post-BMT mice. |
2,336,836 | Cost-benefit, cost-effectiveness and cost-utility analyses of periodontitis prevention. | The aim of this paper was to determine whether there is evidence that periodontitis prevention is economically justified.</AbstractText>The characteristics of economic assessments such as cost-benefit, cost-effectiveness and cost-utility analyses were first derived from the literature on health economy. A literature search was conducted using PubMed up to December 2004. Inclusion criteria required that economic analyses be based on scientific principles including a hypothesis, valid comparative groups as well as a cost/benefit, cost/effectiveness and cost/utility assessment.</AbstractText>Only 14 papers were located, which included, in the broadest sense, economic parameters. From these papers, three were systematic reviews, three were randomized controlled studies, four were controlled studies, one was a longitudinal cohort study and three papers were based on statistical modelling. Only one paper reported actual costs for periodontal and dental treatment. Extensive programmes aimed at prevention of periodontal disease in a general population group showed no economic benefit. Adjunctive genetic/and or microbiological testing likewise showed no economic benefit. Economic assessments and real costs are not generally available in the literature. Statistical modelling suggested that non-surgical periodontal procedures are more economical compared with surgical interventions. The use of local delivery devices as an adjunct to Sc/RP showed no economic advantage.</AbstractText>It is suggested that economic parameters as well as patient-centred outcomes be included in clinical trials. These data are essential for the appropriate allocation of resources for preventive measures on an individual patient and population base.</AbstractText> |
2,336,837 | Medical nanotechnology: shortening clinical trials and regulatory pathways? | Nanotechnology, the science of creating structures, devices, and systems with a length scale of approximately 1-100 nanometers, is poised to have a revolutionary effect on biomedical research and clinical science. By operating at the same scale as most biomacromolecules, nanoscale devices can afford a detailed view of the molecules and events that drive cellular systems and that lie at the heart of disease, and thus, nanotechnology can impact the drug discovery, development, and clinical testing of novel pharmaceuticals. Already, nanoscale drug delivery vehicles are in clinical use, but those successes represent just one way in which nanotechnology will prove useful. One promising nanoscale technology under development may provide real-time, in vivo measurements of apoptosis, and thus may afford an early signal of therapeutic efficacy, both in human clinical trials and in preclinical screening. Microfluidic systems, built of nanoscale components, can enable a host of rapid, massively parallel, high-throughput screening systems, while nanoscale sensors in a wide variety of formats are ready to provide multiplexed biochemical and genetic measurements in living systems. These advances could be utilized to shave time and expense from multiple stages of the drug discovery and development effort. |
2,336,838 | Hereditary non-polipomatous colorectal cancer: hereditary predisposition, diagnosis and prevention. | Colorectal cancer is the third in frequency and the second in mortality in developed countries. In Brazil, it is among the six more common malignant neoplasias. About 20% of colorectal tumors have some hereditary component.</AbstractText>This study presents a review of genetic and clinic aspects, as well as diagnosis and prevention of the hereditary non-polipomatous colorectal cancer, that is the more frequent form of hereditary colorectal cancer. This approach is important because, currently there are possibilities of management, prevention and surveillance specific to individuals at-risk for hereditary non-polipomatous colorectal cancer that can lead to a great improvement in patients' survival and their at-risk relatives.</AbstractText> |
2,336,839 | A noninvasive genetic screening test to detect oral preneoplastic lesions. | Early diagnosis of oral squamous cell carcinoma (OSCC) may have a major impact on survival and quality of life. Recent studies have shown that the majority of OSCC is preceded by precursor lesions characterized by genetic alterations. The aim of this study was to develop and evaluate a noninvasive screening test for oral preneoplastic lesions, based on genetic alterations as marker. Various methods to obtain a high yield of cells by brushing a small area of the oral mucosa were compared. A novel genetic assay, multiplex ligation-dependent probe amplification (MLPA), was applied that enables the measurement of gains and losses at 40 different chromosomal locations in one PCR reaction using 150 ng DNA. MLPA was performed on DNA of normal and dysplastic oral mucosa as well as of OSCC with the intention to select a specific probe set for accurate detection of precursor lesions in the oral cavity. The assay was correlated to loss of heterozygosity analysis using microsatellite markers, and evaluated on noncancer subjects and patients with oral leukoplakia. A noninvasive sampling method was developed with DNA yields ranging from 150 to 600 ng. Using 120 probes, we could detect large differences with MLPA in the number of alterations between normal vs dysplastic and dysplastic vs tumor tissue with P-values <0.001. A significant correlation was found between the number of alterations as detected by MLPA and the analysis for allelic loss. The available data enabled the selection of a set of 42 MLPA probes, which had the power to optimally discriminate between normal and dysplastic tissue. Our data show that MLPA is a sensitive, reliable, high-throughput and easy-to-perform technique, enabling the detection of genetic alterations on small noninvasive samples and can be considered a promising method for population-based screening of preneoplastic lesions in the oral cavity. |
2,336,840 | Association between polymorphisms in the progesterone receptor gene and endometriosis. | The progesterone receptor (PR) is a candidate gene for the development of endometriosis, a complex disease with strong hormonal features, common in women of reproductive age. We typed the 306 base pair Alu insertion (AluIns) polymorphism in intron G of PR in 101 individuals, estimated linkage disequilibrium (LD) between five single-nucleotide polymorphisms (SNPs) across the PR locus in 980 Australian triads (endometriosis case and two parents) and used transmission disequilibrium testing (TDT) for association with endometriosis. The five SNPs showed strong pairwise LD, and the AluIns was highly correlated with proximal SNPs rs1042839 (delta2 = 0.877, D9 = 1.00, P < 0.0001) and rs500760 (delta2 = 0.438, D9 = 0.942, P < 0.0001). TDT showed weak evidence of allelic association between endometriosis and rs500760 (P = 0.027) but not in the expected direction. We identified a common susceptibility haplotype GGGCA across the five SNPs (P = 0.0167) in the whole sample, but likelihood ratio testing of haplotype transmission and non-transmission of the AluIns and flanking SNPs showed no significant pattern. Further, analysis of our results pooled with those from two previous studies suggested that neither the T2 allele of the AluIns nor the T1/T2 genotype was associated with endometriosis. |
2,336,841 | Capillaroscopy of the dorsal skin of the hands in hereditary hemorrhagic telangiectasia. | Cutaneous telangiectases are manifestations of hereditary hemorrhagic telangiectasia (HHT), a dominantly inherited disorder. Telangiectases have been studied by skin biopsy, and recently by nailfold capillaroscopy.</AbstractText>To confirm the diagnostic role of nailfold capillaroscopy, and assess the value of skin capillaroscopy of the dorsum of the hands in HHT.</AbstractText>Prospective clinical investigation.</AbstractText>Using a Wild Heerbrugg-M650 microscope, we studied the nailfolds and dorsum of the hands of 88 patients (37 females, 51 males, mean age 39.7 +/- 18.4 years), including 85 with positive genetic testing and three with clinical diagnosis (at least three clinical criteria but a negative genetic test) and 27 controls (13 females, 14 males, mean age 38.6 +/- 19.6 years).</AbstractText>Microscopic telangiectases were observed on the dorsum of the hands in 80/88 patients (91%): 77 with positive and three with negative genetic tests. No control showed vascular abnormalities. In six patients (7%), nailfold capillaroscopy showed pseudo-megacapillaries and megacapillaries; the remaining 82 (93%) and all controls, had normal capillaroscopic patterns.</AbstractText>HHT can induce morphological changes in microcirculation that are more easily detectable on the dorsum of the hands than in the nailfold. Microscopic lesions without macroscopic telangiectases were also noted, suggesting the need for further research. Capillaroscopy may provide an additional non-invasive diagnostic criterion for HHT.</AbstractText> |
2,336,842 | Highly parallel microbial diagnostics using oligonucleotide microarrays. | Oligonucleotide microarrays are highly parallel hybridization platforms, allowing rapid and simultaneous identification of many different microorganisms and viruses in a single assay. In the past few years, researchers have been confronted with a dramatic increase in the number of studies reporting development and/or improvement of oligonucleotide microarrays for microbial diagnostics, but use of the technology in routine diagnostics is still constrained by a variety of factors. Careful development of microarray essentials (such as oligonucleotide probes, protocols for target preparation and hybridization, etc.) combined with extensive performance testing are thus mandatory requirements for the maturation of diagnostic microarrays from fancy technological gimmicks to robust and routinely applicable tools. |
2,336,843 | Genetic testing for pharmacogenetics and its clinical application in drug therapy. | There is wide individual variation in drug responses and adverse effects. As the main causes of the variation in drug responses, attention has focused on the genetic polymorphisms that encode metabolic enzymes regulating pharmacodynamics and receptors modulating the affinity with the responsive sites. Tailor-made drug therapy analyzes genetic polymorphisms involved in drug responses before drug administration and selects drugs and doses suitable for the individual genetic background. Establishment of tailor-made drug therapy is expected to contribute to medical economy by avoiding wasteful drug administration. To promote such medical practice, it is necessary to use simple genetic testing that is clinically convenient. Currently, genetic testing using real-time PCR has been frequently employed at laboratories with its clinical application anticipated. As to the many genes involved in drug responses, to date, the application of patient genetic information to tailor-made drug therapy has been achieved at the practical level. Information on pharmacogenetics will be a critical factor in medical practice in the near future. |
2,336,844 | Ethnicity and mutations in GJB2 (connexin 26) and GJB6 (connexin 30) in a multi-cultural Canadian paediatric Cochlear Implant Program. | To determine the relationship between ethnicity and mutations in the GJB2 and GJB6 genes in multi-cultural patients enrolled in a Canadian paediatric Cochlear Implant Program.</AbstractText>Blood was analyzed from 65 paediatric cochlear implant users by direct sequencing of the coding region and intron/exon boundaries of the GBJ2 gene. Individuals heterozygous for one mutation in GJB2 or in whom mutations in GJB2 were not detected were analyzed for the common 342 kb deletion mutation D13S1830 in the GJB6 gene. Information regarding ethnicity of patients' families was obtained from patient records and/or interview.</AbstractText>GJB2 mutations were found in 36.9% of paediatric cochlear implant users tested. Nine different GJB2 mutations were identified among individuals from 14 different countries of origin. Seventy-eight percent of all identified pathogenic GJB2 mutations were 35delG. Biallelic GJB2 mutations were found in 16 cochlear implant users (66.7% of GJB2 mutations). Three novel GJB2 sequence changes were identified: (1) a missense mutation T107C (L36P) in an individual of African decent; (2) a missense mutation G475T (D159Y) in an individual of Caribbean decent; (3) a regulatory region change 1-34C to T in an individual of African decent. GJB6-D13S1830 mutations were not found in any of the patients tested. Individuals of African, Caribbean and East Indian decent had different GJB2 mutations than the remainder of individuals tested. Patients of Asian, Italian, Spanish, Polish and Armenian decent were not found to carry mutations in GJB2 or the common GJB6-D13S1830 mutation.</AbstractText>This study represents the largest number of biallelic GJB2 mutations isolated in a group of paediatric cochlear implant users to date. Numerous and diverse GJB2 mutations were found in this multi-cultural group of children. Even though GJB2 mutations have been widely reported in the literature, this discussion represents the first report of GJB2 mutations in a multi-ethnic population (Canadian), as compared with previous studies that investigated fairly homogeneous populations. The diversity of GJB2 mutations identified reinforces the importance of testing for changes in GJB2 by direct sequencing of the entire coding region rather than testing only for common mutations.</AbstractText> |
2,336,845 | Complex genetics of glaucoma susceptibility. | Glaucoma describes a group of diseases that kill retinal ganglion cells. There are different types of glaucoma, and each appears to be genetically heterogeneous. Different glaucoma genes have been identified, but these genes account for only a small proportion of glaucoma. Most glaucoma cases appear to be multifactorial, and are likely affected by multiple interacting loci. A number of genetic susceptibility factors have been suggested to contribute to glaucoma. These factors fit into two broad groups, those affecting intraocular pressure and those important in modulating retinal ganglion cell viability. Defining the complex genetics of glaucoma will require significant further study of the human disease and animal models. Genetic approaches are essential and will be enhanced by recently developed genomic and proteomic technologies. These technologies will provide valuable clues about pathogenesis for subsequent testing. In this review, we focus on endogenous genetic susceptibility factors and on how experimental studies will be valuable for dissecting the multifactorial complexity of their interactions. |
2,336,846 | Estimating the attitude of immigrants toward primary prevention of the hemoglobinopathies. | We conducted population specific confidential enquiries among immigrants who had never experienced hemoglobinopathies, to study the reliability of this approach in estimating the wish for primary prevention by prenatal diagnosis and selective abortion.</AbstractText>We collected data from Surinamese Hindustanis (n = 119), Surinamese and Antillean Afro-Americans (n = 105) and North Africans (mainly Moroccans) (n = 102), living in Holland. We also interviewed 105 informed individuals of different ethnicities, all members of the multi-ethnic patients and carriers' organization 'OSCAR Nederland'.</AbstractText>On average, 68% of the Surinamese Hindustanis and 42% of the Surinamese Afro-Americans were in favor of selective abortion in case of affected pregnancy. Remarkably, 77% of the last group wanted to be tested for carrier diagnostics and 67% declared to have knowledge of the disease before they were informed. Only 16% of the Moroccans were in favor of selective abortion in case of an affected fetus, while 79% wanted to have blood analysis to establish their carrier status.</AbstractText>The apparently limited wish for selective abortion expressed by Moroccans is in contrast with the high number of illegal abortions reported among married women in Morocco (39%). The wish for selective abortion among informed members of the patients' organization was more than 80%.</AbstractText>Copyright 2005 John Wiley & Sons, Ltd.</CopyrightInformation> |
2,336,847 | Genotype-phenotype correlation of mouse pde6b mutations. | To identify the underlying molecular defects causing retinal degeneration in seven N-ethyl-N-nitrosourea (ENU) induced mutant alleles of the Pde6b gene and to analyze the timescale of retinal degeneration in these new models of retinitis pigmentosa.</AbstractText>Conformation sensitive capillary electrophoresis and DNA sequencing were used to identify the mutations in the Pde6b gene. Visual acuity testing was performed with a visual-tracking drum at ages ranging from postnatal day 25 to week 10. Retinal examination was performed with an indirect ophthalmoscope. Animals were killed and eyes were prepared for histologic analysis.</AbstractText>Point mutations in the seven new alleles of Pde6b were identified: Three generated premature stop codons, two were missense mutations, and two were splice mutations. The three stop codon mutants and one of the splice mutants had phenotypes indistinguishable from the Pde6b(rd1) mouse in rapidity of onset of retinal degeneration, suggesting that they are null alleles. However, the remaining alleles showed slower onset of retinal degeneration, as determined by visual acuity testing, fundus examination, and histology, indicating that they are hypomorphic alleles.</AbstractText>These data demonstrate a correlation between genotype and phenotype. Four of the mutants with severe genetic lesions have rapid onset of retinal degeneration, as determined by fundus examination. These mice were indistinguishable from Pde6b(rd1) mice, which are effectively blind by 3 weeks of age. In contrast, the milder genetic lesions show a slower progression of the disease and provide the community with models that more closely mimic human retinitis pigmentosa.</AbstractText> |
2,336,848 | Late-onset macular degeneration and long anterior lens zonules result from a CTRP5 gene mutation. | To identify the gene responsible for a complex ocular phenotype of late-onset macular degeneration, long anterior zonules (LAZ), and elevated intraocular pressure (IOP) and to study its expression.</AbstractText>Ocular examination, visual field, fluorescein angiography, and electrophysiology testing were performed. One affected individual was treated with vitamin A. DNA from 55 family members (UM:H389) was used for linkage, mapping, and mutation analysis. Linkage analysis of macular degeneration and LAZ phenotypes was performed independently. Mutations in candidate genes were screened by sequencing. mRNA expression of CTRP5 and MFRP, which are bicistronic genes, was studied by semiquantitative RT-PCR (qRT-PCR) in various human tissues. CTRP5 expression was also evaluated by in situ hybridization.</AbstractText>Affected members had LAZ detectable by the third decade and/or macular degeneration by the fourth to fifth decade. A six-month treatment with vitamin A shortened dark adaptation considerably in one affected member. Both conditions mapped independently with zero recombination to 11q23, with maximum lod scores of 3.31 for macular degeneration and 5.41 for LAZ. The same CTRP5 missense mutation was identified in all affected individuals. Retinal pigment epithelium (RPE) and ciliary epithelium (CE) showed highest CTRP5 transcript expression, which was also true for MFRP. CTRP5 tissue expression was confirmed by in situ hybridization.</AbstractText>A single locus at 11q23 is implicated in a complex ocular phenotype involving RPE and CE, tissues of neuroectodermal origin. All individuals with either LAZ and/or macular degeneration carry the same CTRP5 S163R mutation, which is transmitted in autosomal dominant manner.</AbstractText> |
2,336,849 | Sequencing arrays for screening multiple genes associated with early-onset human retinal degenerations on a high-throughput platform. | To develop and apply microarray-based resequencing technology to detect sequence alterations in multiple autosomal recessive retinal disease genes on a single high-throughput platform.</AbstractText>Oligonucleotides corresponding to both strands of the target exons and the flanking intron sequences of 29,214 bp from 11 genes associated with autosomal recessive retinitis pigmentosa (arRP) were tiled on 20 x 25-microm microarrays (arRP-I arrays). A total of 155 exons were amplified from 35 arRP patient DNA samples, with each sample being sequenced on an arRP-I chip by hybridization.</AbstractText>With the arRP-I arrays, 97.6% of the tiled sequence were determined with more than 99% accuracy and reproducibility. Of the 2.4% unread sequence, 89.5% involved stretches of G or C. In analyzing the 903,140-bp sequence from the 35 patient samples, 506 sequence changes have been detected in which 386 are previously reported alterations, and 120 are novel. In addition to four known causative mutations, six novel sequence changes that are potentially pathogenic were observed. Additional analysis is needed to determine whether these changes are responsible for arRP in these patients.</AbstractText>The use of microarray for sequencing is a novel approach, and the arRP-I chip is the first successful application of this technology for determining sequence alteration in multiple disease-related genes. These arrays can be used for high-throughput genotyping of patients with relevant retinal conditions. In addition, these arrays offer a unique opportunity to interrogate complex patterns of inheritance due to the involvement of more than one gene by screening multiple genes on a single platform.</AbstractText> |
2,336,850 | Different HLA class IA region complotypes for HLA-A29.2 and -A29.1 antigens, identical in birdshot retinochoroidopathy patients or healthy individuals. | Birdshot retinochoroidopathy (BSCR) is a rare posterior uveitis characterized by distinctive, multiple, hypopigmented choroidal and retinal lesions. At least 96% of patients, if not all, share the major histocompatibility antigen HLA-A29. Although it was hypothesized earlier that more frequently the A*2902 subtype was closely associated with BSCR, new patients were found to share the A*2901 subtype and were further investigated. The present study was designated to check patients' HLA-A*2901 subtyping and the polymorphisms available in the HLA region in patients and control subjects sharing the A*2901 and A*2902 subtypes.</AbstractText>HLA-A29 was assessed and subtyped by molecular biology. cDNA from one patient (HLA-A*2901) was sequenced. A29.1 antigenic expression on peripheral blood lymphocytes was checked by microlymphocytotoxicity (MLCT). Four homozygous A29.2 and 4 heterozygous A29.2 patients, 3 homozygous A29.2 healthy subjects, 3 heterozygous A29.1 patients, and 11 heterozygous A29.1 healthy subjects were tested for the microsatellite alleles MOGa, -b, -c, and e (of the myelin oligodendrocyte glycoprotein [MOG]gene), D6S265, D6S510, RF, C5_4_5, D6S105, and D6S276 and the mutation H63D of the familial hemochromatosis gene (HFE).</AbstractText>The patients' cDNA sequences and MLCT reactivities of HLA-A29.1 subtypes were found to be identical with published data from healthy individuals. Surprisingly, though A*2901 and A*2902 differed only by a single mutation (G376C/ D102H) two strong A*2901 and A*2902 complotypes were observed in patients and control subjects, the polymorphisms being identical at all loci near HLA-A, whereas more distant loci exhibited some diversity.</AbstractText>Susceptibility to BSCR thus appeared to be located between the left and right remote markers C5_4_5 and D6S276, if not relying on the HLA-A29 molecule itself.</AbstractText> |
2,336,851 | Genome-wide analyses demonstrate novel loci that predispose to drusen formation. | To test whether genes for drusen formation are independent of age-related macular degeneration (AMD) pathogenesis.</AbstractText>A genome-wide model-free linkage analysis was performed, using two semiquantitative drusen traits, size and type, on two sets of data: (1) 325 individuals (225 sib pairs) from the Beaver Dam Eye Study (BDES), and (2) 297 individuals (346 sib pairs) from the Family Age Related Maculopathy Study (FARMS). Apolipoprotein E (APOE) genotypes were used as a covariate in a multipoint sibpair analysis.</AbstractText>The authors found evidence of linkage on 19q13.31 (D19S245), with size of drusen in both the BDES (P = 0.0287) and the FARMS (P = 0.0013; P = 0.0005, combined). In the BDES, type showed linkage evidence on 3p24.3 (D3S1768; P = 0.0189) and 3q25.1 (D3S2404; P = 0.0141); the linkage on 3p24.3 was also found with size (D3S1768; P = 0.0264). In the FARMS, size showed evidence of linkage at 5q33.3 (D5S820; P = 0.0021), 14q32.33 (D14S1007; P = 0.0013), and 16p13.13 (D16S2616; P = 0.0015) and type at 21q21.2 (D21S2052; P = 0.0070). For size in the FARMS, there was a small increase in P-value at marker D19S245 from 0.0044 to 0.0111, and from 0.0044 to 0.0064, when the epsilon4-carrier and the epsilon3-carrier genotype were the covariates, respectively.</AbstractText>The results show that APOE effects may be mediated early in the progression of ARM to AMD and thus may not be detected by standard genome scans for more severe disease.</AbstractText> |
2,336,852 | Genotyping microarray (disease chip) for Leber congenital amaurosis: detection of modifier alleles. | Leber congenital amaurosis (LCA) is an early-onset inherited disorder of childhood blindness characterized by visual impairment noted soon after birth. Variants in at least six genes (AIPL1, CRB1, CRX, GUCY2D, RPE65, and RPGRIP1) have been associated with a diagnosis consistent with LCA or early-onset retinitis pigmentosa (RP). Genetically heterogeneous inheritance complicates the analyses of LCA cases, especially in patients without a family history of the disorder, and conventional methods are of limited value.</AbstractText>To overcome these limitations, arrayed primer extension (APEX) technology was used to design a genotyping microarray for early-onset, severe retinal degenerations that includes all of the >300 disease-associated variants currently described in eight genes (in addition to the six just listed, the early-onset RP genes LRAT and MERTK were added). The resultant LCA array allows simultaneous detection of all known disease-associated alleles in any patient with early-onset RP. The array was validated by screening 93 confirmed patients with LCA who had known mutations. Subsequently, 205 novel LCA cases were screened on the array, followed by segregation analyses in families, if applicable.</AbstractText>The microarray was >99% effective in determining the existing genetic variation and yielded at least one disease-associated allele in approximately one third of the novel patients. More than two (expected) variants were discovered in a substantial fraction (22/300) of the patients, suggesting a modifier effect from more than one gene. In support of the latter hypothesis, the third allele segregated with a more severe disease phenotype in at least five families.</AbstractText>The LCA genotyping microarray is a robust and cost-effective screening tool, representing the prototype of a disease chip for genotyping patients with a genetically heterogeneous condition. Simultaneous screening for all known LCA-associated variants in large LCA cohorts allows systematic detection and analysis of genetic variation, facilitating prospective diagnosis and ultimately predicting disease progression.</AbstractText> |
2,336,853 | PAWE-3D: visualizing power for association with error in case-control genetic studies of complex traits. | A website that plots power and sample size calculations over a range of up to eight parameters (including diagnostic misclassification error parameters) for two commonly used statistical tests of genetic association, the linear trend test and the genotypic test of association.</AbstractText>This method is made available via the website http://linkage.rockefeller.edu/pawe3d/</AbstractText>pawe3d@linkage.rockefeller.edu.</AbstractText> |
2,336,854 | Preimplantation genetic diagnosis: the ethics of intermediate cases. | According to the current guiding principle regarding preimplantation genetic diagnosis (PGD), the technique should focus on the diagnosis of genetic defects which (may) affect the health of this particular potential child--the so-called 'medical model'. I argue in favour of a more permissive view, also allowing PGD of characteristics which may be relevant for the health of 'third parties'. Two cases are analysed: PGD/HLA typing in order to save a sib, and PGD/sex selection in order to prevent the birth of healthy female carriers of X-linked recessive disorders, who are at high risk of conceiving affected sons. While these cases are at odds with the medical model stricto sensu, they do have a link with health problems. In the first case, the health benefit hoped for is intrafamilial, in the second case the health benefit is transgenerational. These cases illustrate that the traditional dichotomy between the medical model on the one hand and the 'designer' or autonomy model on the other hand is simplistic--they represent an intermediate category. |
2,336,855 | The Y chromosome gr/gr subdeletion is associated with male infertility. | Men with Y chromosome (Yq) AZFc deletions lack all copies of the DAZ gene and have severe spermatogenic failure. A recently described gr/gr subdeletion of AZFc removes two of four copies of DAZ. To better understand the relative frequencies of AZFc and gr/gr deletions and their associated phenotypes, we analysed two large groups of infertile men. A total of 788 men from the Monash Male Infertility (MMI) database with a range of fertility disorders showed similar overall prevalences of AZFc (2.5%) and gr/gr deletions (3.4%). There was no association of gr/gr deletions with sperm density. In 234 control men of known or presumed fertility, only one gr/gr deletion was found. In a further 599 consecutive men presenting for assisted reproductive technologies, we detected 13 (2.2%) AZFc deletions and 28 (4.7%) gr/gr deletions. All AZFc deletions were seen with sperm densities <5 million/ml but again the gr/gr deletion occurred with similar frequency across all sperm density categories. These data show that gr/gr deletions are significantly associated with infertility in the Australian population (P = 0.0015) but not exclusively with reduced sperm density suggesting a complex interaction with other factors important for male fertility. Vertical transmission of gr/gr deletions from father to son by ICSI was demonstrated in four cases. Analysis of 130 ICSI-conceived sons revealed no de novo gr/gr deletions indicating that ICSI is not a risk factor. The data suggest that testing for gr/gr deletions should be considered in the routine genetic assessment of men with idiopathic infertility. |
2,336,856 | The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. | The Arg/Arg genotype versus Arg/Pro or Pro/Pro at codon 72 of the p53 gene has been implicated in increasing susceptibility of the cervix to human papillomavirus (HPV) infection and thus altering cancer risk. However, research on this topic has been contentious, which prompted us to carry out a case-control study in the Montreal area.</AbstractText>Cases were women with histologically-confirmed high-grade cervical intraepithelial neoplasia (HGCIN). Controls were women without a history of cervical abnormalities. From each woman, we obtained a cervical specimen for HPV testing and p53 genotyping, and a questionnaire was completed. DNA sequencing was used to minimize genotype misclassification. A subsample of specimens was also genotyped using the TaqMan assay.</AbstractText>There were 357 cases and 760 controls recruited between February 2001 and December 2003. The distribution of Arg/Arg, Arg/Pro and Pro/Pro was 55.2, 36.4 and 8.4%, respectively, among cases, and 52.1, 38.7 and 9.2%, among controls, corresponding to an odds ratio (OR) adjusted for ancestral origin of 1.16 (95% confidence interval (CI): 0.9-1.5) for Arg/Arg versus other genotypes. When restricted to high-risk HPV-positive women, the adjusted ORs were 1.40 (CI: 0.9-2.1) and 2.12 (CI: 1.1-4.2), for Arg/Arg versus other genotypes and versus Pro/Pro, respectively. The findings were comparable with analyses of genotype results that agreed between DNA sequencing and TaqMan.</AbstractText>In this study, we attempted to minimize selection bias, population stratification and genotype misclassification. The results suggest that the role of the p53 codon 72 polymorphism on HGCIN is weak at best. Further research may reveal if the polymorphism has a stronger influence on the risk of invasive cervical cancer.</AbstractText> |
2,336,857 | A novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy. | Aminoglycoside antibiotics have been found to suppress nonsense mutations located in the defective dystophin gene in mdx mice, suggesting a possible treatment for Duchenne muscular dystrophy (DMD). However, it is very difficult to find patients that are applicable for this therapy, because: (1) only 5-13% of DMD patients have nonsense mutations in the dystrophin gene, (2) it is challenging to find nonsense mutations in the gene because dystrophin cDNA is very long (14 kb), and (3) the efficiency of aminoglycoside-induced read-through is dependent on the kind of nonsense mutation. In order to develop a system for identifying candidates that qualify for aminoglycoside therapy, fibroblasts from nine DMD patients with nonsense mutation of dystrophin gene were isolated, induced to differentiate to myogenic lineage by AdMyoD, and exposed with gentamicin. The dystrophin expression in gentamicin-exposed myotubes was monitored by in vitro dystrophin staining and western blotting analysis. The results showed that gentamicin was able to induce dystrophin expression in the differentiated myotubes by the read-through of the nonsense mutation TGA in the gene; a read-through of the nonsense mutations TAA and TAG did not occur and consequently did not lead to dystrophin expression. Therefore, it is speculated that the aminoglycoside treatment is far more effective for DMD patients that have nonsense mutation TGA than for patients that have nonsense mutation TAA and TAG. In this study, we introduce an easy system to identify patients for this therapy and report for the first time, that dystrophin expression was detected in myotubes of DMD patients using gentamicin. |
2,336,858 | Identification of methicillin-resistant Staphylococcus aureus (MRSA): Comparison of a new molecular genetic test kit (GenoType MRSA) with standard diagnostic methods. | Results obtained from 188 isolates of staphylococci using standard diagnostic methods for identifying MRSA were compared with those achieved with a newly available molecular genetic test kit, the GenoType, Version 1, MRSA (Hain Lifescience GmbH, Nehren, Germany). The GenoType MRSA detects the mecA gene and, in addition, a highly specific sequence for Staphylococcus aureus (S. aureus) by polymerase chain reaction (PCR) and reverse hybridization. There was a 100% overall correlation between the results of conventional and molecular genetic testing. 143 isolates were tested positive for MRSA, 10 isolates were identified as oxacillin-sensitive Staphylococcus aureus strains (MSSA), and 35 isolates were coagulase-negative staphylococci of various species. However, five of the 143 MRSA strains yielded ambiguous results with the first line standard tests and therefore required additional testing leading to delay of definitive diagnosis. As expected, mecA could not only be detected in MRSA strains, but also in coagulase-negative staphylococci. The reliable identification as S. aureus from the same isolate is therefore an essential prerequisite for MRSA diagnosis. The GenoType MRSA fulfills this requirement by parallel detection of a S. aureus-specific sequence and the mecA gene. Molecular genetic testing with the GenoType MRSA kit needs much less time than conventional microbiological methods. Therefore genetic testing provides not only a considerable advantage with respect to reliability but also to speed. |
2,336,859 | [More hereditary intestinal cancer can be detected if patients with colorectal carcinoma that are selected by the pathologist are examined for microsatellite instability]. | To determine whether an investigation of microsatellite instability (MSI) in patients with colorectal carcinoma that have been selected by the pathologist could increase the number of detected families with hereditary non-polyposis colorectal carcinoma (HNPCC).</AbstractText>Prospective inventory.</AbstractText>Pathologists selected patients with a newly diagnosed colorectal carcinoma for MSI analysis of their tumour tissue if they met one of the following four criteria: (a) colorectal carcinoma diagnosed below 50 years of age; (b) a second colorectal carcinoma; (c) a combination of colorectal carcinoma and another HNPCC-related cancer; (d) colorectal adenoma with high-grade dysplasia diagnosed below 40 years of age. Patients with a positive MSI-test were referred to a clinical geneticist. The new strategy was introduced and explored in 5 hospitals for a period of to months.</AbstractText>The new strategy was adopted and implemented successfully by pathologists and surgeons and accepted with satisfaction by the patients. Of the 55 patients included, 10 had a positive MSI-test. In 8/10 patients, DNA-mutation analysis was started by the clinical geneticist and 3 germline mutations in the MSH2-gene were detected. In 2 of 3 families with a pathogenic mutation, the family history alone did not fulfil the clinical criteria for HNPCC.</AbstractText>Selection by the pathologist for MSI investigation was feasible in daily practice and identified more HNPCC patients than selection based on family history alone.</AbstractText> |
2,336,860 | Testing association and linkage using affected-sib-parent study designs. | We have developed a method for jointly testing linkage and association using data from affected sib pairs and their parents. We specify a conditional logistic regression model with two covariates, one that quantifies association (either direct association or indirect association via linkage disequilibrium), and a second that quantifies linkage. The latter covariate is computed based on expected identity-by-descend (ibd) sharing of marker alleles between siblings. In addition to a joint test of linkage and association, our general framework can be used to obtain a linkage test comparable to the mean test (Blackwelder and Elston [1985] Genet. Epidemiol. 2:85-97), and an association test comparable to the Family-Based Association Test (FBAT; Rabinowitz and Laird [2000] Hum. Hered. 50:211-223). We present simulation results demonstrating that our joint test can be more powerful than some standard tests of linkage or association. For example, with a relative risk of 2.7 per variant allele at a disease locus, the estimated power to detect a nearby marker with a modest level of LD was 58.1% by the mean test (linkage only), 69.8% by FBAT, and 82.5% by our joint test of linkage and association. Our model can also be used to obtain tests of linkage conditional on association and association conditional on linkage, which can be helpful in fine mapping. |
2,336,861 | Genetic diversity and the evolutionary history of plant immunity genes in two species of Zea. | Plant pathogenesis-related genes (PR genes) code for enzymes, enzyme inhibitors, and other peptides that confer resistance to pathogens and herbivores. Although several PR genes have been the subject of molecular population genetic analyses, a general understanding of their long-term evolutionary dynamics remains incomplete. Here we analyze sequence data from 17 PR genes from two closely related teosinte species of central Mexico. In addition to testing whether patterns of diversity at individual loci depart from expectations under a neutral model, we compared patterns of diversity at defense genes, as a class, to nondefense genes. In Zea diploperennis, the majority of defense genes have patterns of diversity consistent with neutral expectations while at least two genes showed evidence of recent positive selection consistent with arms-race models of antagonistic coevolution. In Zea mays ssp. parviglumis, by contrast, analyses of both defense and nondefense genes revealed strong and consistent departures from the neutral model, suggestive of nonequilibrium population dynamics or population structure. Nevertheless, we found a significant excess of replacement polymorphism in defense genes compared to nondefense genes. Although we cannot exclude relaxed selective constraint as an explanation, our results are consistent with temporally variable (transient or episodic) selection or geographically variable selection acting on parviglumis defense genes. The different patterns of diversity found in the two Zea species may be explained by parviglumis' greater distribution and population structure together with geographic variation in selection. |
2,336,862 | [A linkage map of mirosatellite on chromosome 1 in Liangshan semi-wool sheep]. | The 9 microsatellite markers on Chromosomes 1 were used to construct a linkage map of Liangshan semi-wool sheep with a 387 members half-sib pedigrees after paternity testing. The results were as follows: the number of alleles for 9 markers was from 5 to 15; the heterozygosity was from 0.202 to 0.831, the average heterozygosity was 0.617 and the polymorphic information content (PIC) was 0.604. Length of the linkage map of chromosome 1 we built was 311.0 cM which is in consistent with the sheep linkage map of USDA and IMF, and can be used in Quantitative Trait Loci searching in Liangshan semi-wool sheep. |
2,336,863 | [Generation of RHD-CE(2-9)-D allele by gene conversion in cis]. | Previously a few Rh-negative individuals in Caucasian and Chinese were found existing exons 1 and 10 of RHD through genomic DNA testing. The molecular mechanisms, however, remain disputed. In this study, 2 individuals carrying RHD positive, D antigen negative allele (with exon 1 and 10 of RHD) and their mRNA were investigated by using reverse transcriptase PCR (RT-PCR) and sequencing through one pair of specific primers for 5'- and 3'-non-coding region of RHD, taking a Rh-positive (Ccee) sample as control. As a result, the control sample had a normal RHD mRNA, whereas other transcripts were detected in both RHD-positive, D antigen negative individuals, which have same length and exons as the normal RHD or RHCE mRNA. Those transcripts had the same sequences with RHD in exon 1 and exon 10, while the sequences in exons 2-9 were in concordance with RHCE(e) mRNA. It indicated that a hybrid RHD allele, RHD-CE(2-9)-D, was existed in the 2 individuals, in which the exons 2-9 of RHD were substituted by homologous RHCE(e). Thus, this allele could not code normal RhD protein and therefore resulted in Rh-negative phenotype. |
2,336,864 | [A family with nonsyndromic hearing impairment caused by intermarry]. | Deafness is the most prevalent sensory system impairment in human, about 70 % of genetic deafness belongs to nonsyndromic hearing impairment. It was estimated that the total number of genes involved in nonsyndromic hereditary deafness was over 100. So far, approximate 80 loci have been mapped to human chromosome, and 23 genes have been identified. In this paper, a family with nonsyndromic hearing impairment caused by intermarry was reported. There were 13 sufferers in two generations. Deduced from genetic analysis, neither autosomal dominant nor autosomal recessive inheritance was identified in this family, which suggested that hearing impairment in the family was probably caused by mitochondrial mutations. |
2,336,865 | Analysis of variation in expression of autosomal dominant osteopetrosis type 2: searching for modifier genes. | Autosomal Dominant Osteopetrosis type II (ADO2) is a heritable osteosclerotic disorder that results from heterozygous mutations in the ClCN7 gene. Analysis of ADO2 in our pedigrees indicates that the penetrance is 66%, with a highly variable phenotype.</AbstractText>To identify genes that modify disease status, we performed a 10 cM genome-wide scan using 400 microsatellite markers in 112 subjects from our 8 largest ADO2 families with mutations in the ClCN7 gene. Results were analyzed by parametric linkage analysis using autosomal dominant and recessive models for affects on disease status. Follow-up genotyping with additional microsatellite markers was performed for regions with LOD scores over 1.5. In addition, we compared the frequency of two nonsynonymous SNPs, rs12926089 (V418M) and rs11559208 (K691E), and one promoter SNP rs960467 in the normal ClCN7 allele between a sample of unaffected gene carriers and clinically affected subjects to test the hypothesis that genetic variation in the non-disease allele within the ClCN7 gene might influence disease expression.</AbstractText>We found potential evidence of linkage for a modifier gene(s) on 9q21-22 with a LOD score of 1.89, which is not statistically significant, but interesting. We also found that, for SNP V418M on the non-disease allele with the wild-type ClCN7 sequence, 94.92% (56/59) of clinically affected subjects and 78.13% (25/32) of unaffected gene carriers had a valine while 5.08% (3/59) of the affected subjects and 21.88% (7/32) of unaffected gene carriers had a methionine (P < 0.03). Unfortunately, SNP K691E was not informative in our families. For SNP rs960467, on the non-disease allele with the wild-type ClCN7 gene, 87.93% (51/58) of clinically affected subjects and 62.50% (20/32) of unaffected gene carriers had a C allele while 12.07% (7/58) of the clinically affected subjects and 37.50% (12/32) of unaffected gene carriers had a T allele (P < 0.007). As expected, the polymorphisms on the disease allele were not associated with disease status.</AbstractText>Chromosome 9q21-22 may harbor a modifier gene(s) that affect(s) ADO2 disease status and severity. Additionally, we find the associations between the polymorphisms on the non-disease allele and unaffected gene carrier status.</AbstractText> |
2,336,866 | Detecting deletions in families affected by a dominant disease by use of marker data. | A method of testing for whether inherited deletions are a cause of a single-locus dominant disease was derived, involving analysis of the marker segregation within the pedigree of a single family that segregates for the disease. It is shown that markers can be used to test deductively for the presence of an inherited deletion. The probabilities of confirming or rejecting the presence of a deletion in an arbitrary pedigree without inbreeding are then derived. The power of the test is shown to be limited in single trios but to increase rapidly as the size of the pedigree increases. For larger pedigrees, the probabilities of confirming or rejecting a deletion are higher than 0.9 for SNPs having a minor allele frequency greater than 0.4. The probabilities are higher using multiallelic markers such as microsatellites, reaching levels as high as 0.9 in even rather small pedigrees. In certain cases the test outcome is not deductive, a deletion being neither confirmed nor rejected. It is shown to still be possible then to employ a statistical test for the presence of a deletion by use of an a priori probability for a deletion. |
2,336,867 | Evaluation of Nyholt's procedure for multiple testing correction. | A simple method for accounting efficiently for multiple testing of many SNPs in an association study was recently proposed by Nyholt, but its performance was not extensively evaluated. The method involves estimating an 'effective number' of independent tests and then adjusting the smallest observed p value using Sidák's formula based on this number of tests. We sought to carry out an empirical and theoretical evaluation of Nyholt's method.</AbstractText>Nyholt's method was applied to a sample of 31 genes typed at a total of 291 SNPs and permutation used to determine the type-I error rate for each gene. Based on our empirical results, we algebraically investigated the effective number of independent tests for a simple model of haplotype block structure.</AbstractText>The nominal 5% type I error rate varied from under 3% to over 7%, and was dependent on linkage disequilibrium. Theoretical considerations show further that the method can be very conservative in the presence of haplotype block structure.</AbstractText>Although Nyholt's approach may be useful as an exploratory tool, it is not an adequate substitute for permutation tests.</AbstractText>Copyright 2005 S. Karger AG, Basel.</CopyrightInformation> |
2,336,868 | Finding fibrosis genes: the lung. | Many people are exposed to environmental risk factors for fibrosis, yet only a subset go on to develop disease. It is likely that a number of tissue-specific disease genes determine the path an individual will follow upon exposure to an environmental agent, and that individuals who carry certain combinations of these genes are most susceptible. Diseases which have multiple genetic and environmental determinants, known as "complex traits," present a formidable challenge for gene discovery as the combined influence of more than one gene and one or more environmental factors decrease power to isolate the effect of any single gene. Nevertheless, the identification of the genetic differences that underlie susceptibility to fibrotic disease is crucial to understanding the disease process and to the development of effective screening tests and treatments. No single strategy or method will likely be sufficient to link a candidate disease gene to a fibrosis phenotype. Therefore, we present techniques and resources that can be used in combination to dissect the genetics of complex traits and yield viable candidate genes. Testing of candidate genes and standards for formal proof of gene discovery are discussed. |
2,336,869 | Heterozygous insertions alter crossover distribution but allow crossover interference in Caenorhabditis elegans. | The normal distribution of crossover events on meiotic bivalents depends on homolog recognition, alignment, and interference. We developed a method for precisely locating all crossovers on Caenorhabditis elegans chromosomes and demonstrated that wild-type animals have essentially complete interference, with each bivalent receiving one and only one crossover. A physical break in one homolog has previously been shown to disrupt interference, suggesting that some aspect of bivalent structure is required for interference. We measured the distribution of crossovers in animals heterozygous for a large insertion to determine whether a break in sequence homology would have the same effect as a physical break. Insertions disrupt crossing over locally. However, every bivalent still experiences essentially one and only one crossover, suggesting that interference can act across a large gap in homology. Although insertions did not affect crossover number, they did have an effect on crossover distribution. Crossing over was consistently higher on the side of the chromosome bearing the homolog recognition region and lower on the other side of the chromosome. We suggest that nonhomologous sequences cause heterosynapsis, which disrupts crossovers along the distal chromosome, even when those regions contain sequences that could otherwise align. However, because crossovers are not completely eliminated distal to insertions, we propose that alignment can be reestablished after a megabase-scale gap in sequence homology. |
2,336,870 | Impact of teenage oral contraceptive use in a population-based series of early-onset breast cancer cases who have undergone BRCA mutation testing. | Oral contraceptive (OC) use in young women has been associated with an increased risk of breast cancer. This matched case-control study aims to elucidate the combined effects of OC use and genetic factors in a population-based series of BRCA1/2 mutation-tested early-onset breast cancers. A first invasive breast cancer was diagnosed in 259 women aged 40 years between 1990 and 1995 in the South Swedish Health Care Region. A total of 245 women were included in this study. Information on family history of cancer, reproductive factors, smoking and OC use was obtained from questionnaires or patient charts. Three age-matched controls per case were chosen from a prospective South Swedish cohort. Ever OC use and current OC use were not associated with breast cancer. Cases were more likely to have used OCs before age 20 years (adjusted odds ratio (OR) 2.10 (95% CI 1.32-3.33)) and before their first child (adjusted OR 1.63 (95% CI 1.02-2.62)). When stratified by age, the effect of early OC use was limited to women diagnosed prior to age 36 years (OR 1.53 (1.17-1.99) per year of OC use prior to age 20 years). The risks were similar for low-dose and high-dose OCs. The probability of being a BRCA1/2 mutation carrier was three times higher among cases who started OC use prior to age 20 years compared with cases who started at age 20 years or older or who had never used OCs. However, the duration of OC use was similar among cases with and without BRCA1/2 mutations. No association was seen with a first-degree family history of breast cancer. Each year of OC use prior to age 20 years conferred a significantly increased risk for early-onset breast cancer, while there was no risk associated with use after age 20 years. |
2,336,871 | Identification of mutations in the GNPTA (MGC4170) gene coding for GlcNAc-phosphotransferase alpha/beta subunits in Korean patients with mucolipidosis type II or type IIIA. | Mucolipidosis types II and III are autosomal recessive inherited diseases caused by a deficiency in the lysosomal enzyme N-acetylglucosamine-1 phosphotransferase (GlcNAc-phosphotransferase), which adds phosphate to function as a recognition marker for the uptake and transport of lysosomal enzymes. We investigated mutations in the GNPTA (MGC4170) gene, which codes for the alpha/beta subunits of phosphotransferase, and in the GNPTAG gene, which codes for its gamma subunits in five Korean patients with mucolipidosis type II or IIIA. We identified seven mutations in the GNPTA gene, but none in GNPTAG. The mutations in type II patients included p.Q104X (c.310C>T), p.R1189X (c.3565C>T), p.S1058X (c.3173C>G), p.W894X (c.2681G>A), and p.H1158fsX15 (c.3474_3475delTA), all of which are nonsense or frameshift mutations. However, a splicing site mutation, IVS13+1G>A (c.2715+1G>A) was detected along with a nonsense or a frameshift mutation (p.R1189X or p.E858fsX3 (c.2574_2575delGA)) in two mucolipidosis type IIIA patients. This report shows that mutations in the GNPTA gene coding for the alpha/beta subunits of phosphotransferase, and not mutations in the GNPTAG gene, account for most of the genetic mutations found in Korean patients with mucolipidosis type II or IIIA. |
2,336,872 | Survival analysis of presumptive prognostic markers among oligodendrogliomas. | Allelic losses of 1p and 19q arms correlate with the oligodendroglial phenotype as well as with sensitivity to radiotherapy and chemotherapy. Furthermore, the DNA repair gene, methylguanine methyltransferase (MGMT), is diminished in 80% of oligodendroglial tumors and represents a possible mechanism for this therapeutic sensitivity. However, the authors questioned the relevance of genetic testing and measuring MGMT levels in tumors that were diagnostic of oligodendroglioma.</AbstractText>The authors performed a retrospective analysis of 1p, 19q, 9p21, TP53, and MGMT status in 46 patients with oligodendrogliomas to address any relations that may exist among these markers with regard to progression-free survival (PFS) and total survival. Methodologies included comparative genomic hybridization; loss of heterozygosity (LOH) on 1p, 19q, and 9p21; TP53 mutational analysis; and immunohistochemistry for MGMT.</AbstractText>The authors found that survival among patients with light microscopically diagnosed oligodendroglial tumors demonstrating LOH of 1p and 19q trended toward statistical significance (P = 0.102 and P = 0.058, respectively). 9p21 LOH was significant as a predictor of PFS only among anaplastic oligodendrogliomas in this cohort (P = 0.033). TP53 mutation was found to be significantly predictive of a shorter survival (P = 0.027) among all patients and exhibited a strong trend toward a shorter PFS (P = 0.060). Low-level MGMT labeling index (LI) (< 20%) was noted in 86% of all oligodendroglial tumors. MGMT LI was not found to correlate with an improved PFS or total survival in this cohort, recognizing that median survival was not reached after a median follow-up of 104 months.</AbstractText>9p21 and TP53 mutational status assisted in developing a stricter subclassification of these tumors with prognostic significance. MGMT levels were decreased in a majority of oligodendrogliomas.</AbstractText>Copyright 2005 American Cancer Society</CopyrightInformation> |
2,336,873 | Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. | The relationships between mismatch repair (MMR) protein expression, microsatellite instability (MSI), family history, and germline MMR gene mutation status have not been studied on a population basis.</AbstractText>We studied 131 unselected patients with colorectal cancer diagnosed younger than age 45 years. For the 105 available tumors, MLH1, MSH2, MSH6, and PMS2 protein expression using immunohistochemistry (IHC) and MSI were measured. Germline DNA was screened for hMLH1, hMSH2, hMSH6, and hPMS2 mutations for the following patients: all from families fulfilling the Amsterdam Criteria for hereditary nonpolyposis colorectal cancer (HNPCC); all with tumors that were high MSI, low MSI, or that lacked expression of any MMR protein; and a random sample of 23 with MS-stable tumors expressing all MMR proteins.</AbstractText>Germline mutations were found in 18 patients (nine hMLH1, four hMSH2, four hMSH6, and one hPMS2); all tumors exhibited loss of MMR protein expression, all but one were high MSI or low MSI, and nine were from a family fulfilling Amsterdam Criteria. Sensitivities of IHC testing, MSI (high or low), and Amsterdam Criteria for MMR gene mutation were 100%, 94%, and 50%, respectively. Corresponding positive predictive values were 69%, 50%, and 75%.</AbstractText>Tumor IHC analysis of four MMR proteins and MSI testing provide a highly sensitive strategy for identifying MMR gene mutation-carrying, early-onset colorectal cancer patients, half of whom would have been missed using Amsterdam Criteria alone. Tumor-based approaches for triaging early-onset colorectal cancer patients for MMR gene mutation testing, irrespective of family history, appear to be an efficient screening strategy for HNPCC.</AbstractText> |
2,336,874 | Nocturnal sleep apnea/hypopnea is associated with lower memory performance in APOE epsilon4 carriers. | The authors investigated the relationship between obstructive sleep apnea/hypopnea (OSAH) and cognition in 36 older adults, 18 APOE epsilon4 carriers, and 18 non-carriers. Greater numbers of respiratory events negatively impacted memory function in epsilon4 carriers only. This is the first study to provide preliminary evidence for a negative interaction of APOE epsilon4 and OSAH on memory in older adults, which may have important implications for treating cognitive decline and delaying dementia onset. |
2,336,875 | Evidence of reduced frequency of spinal muscular atrophy type I in the Cuban population. | The authors reviewed all cases of type I spinal muscular atrophy (SMA) in Cuba over a 6-year period. The incidence of SMA type I was 3.53 per 100,000 livebirths. When the population was classified according to self-reported ethnicity, the incidence was eight per 100,000 for whites; 0.89 per 100,000 for blacks, and 0.96 per 100,000 for those of mixed ethnicity. Type 1 SMA may occur less frequently in individuals of African ancestry. |
2,336,876 | A clinical, genetic, and neuropathologic study in a family with 16q-linked ADCA type III. | Presented is the new kindred with autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 (16q-ADCA type III) associated with progressive hearing loss. By haplotype analysis, the critical interval was slightly narrowed to three megabase regions between GATA01 and D16S3095. Neuropathologic study of 16q-ADCA type III demonstrated characteristic shrinkage of Purkinje cell bodies surrounded by synaptophysin-immunoreactive amorphous material containing calbindin- and ubiquitin-positive granules. |
2,336,877 | Neuropsychological function in nondemented carriers of presenilin-1 mutations. | Prospective and case-control studies have demonstrated that memory loss and executive dysfunction occur early in Alzheimer disease (AD).</AbstractText>To investigate these observations by the study of persons at risk for autosomal dominant forms of AD.</AbstractText>Neuropsychological and genetic tests were performed on 51 nondemented at-risk members of 10 Mexican families with two distinct presenilin-1 (PS1) mutations. Test scores were compared between PS1 mutation carriers (MCs; n = 30) and noncarriers (NCs; n = 21) by analyses of variance, co-varying for family and specific mutation. Regression analyses were performed, taking into account age relative to the median age at dementia diagnosis in the family (adjusted age), gender, Beck Depression Inventory (BDI) scores, education, and number of APOE epsilon4 alleles. Subjects were divided into age tertiles and scores compared within these groups. Composite scores for Verbal Memory, Executive Function/Working Memory, Language, and Visuospatial Function were created, and these scores compared between MCs and NCs.</AbstractText>MCs performed worse than NCs on the Mini-Mental State Examination, Trails Making Tests A and B, Delayed Recall of a 10-Word List, and Wechsler Adult Intelligence Scale WAIS Block Design. In multiple linear regression analyses, BDI score, gender, and number of APOE epsilon4 alleles did not consistently affect test scores. The differences seen between MCs and NCs were due to differences in the oldest tertile. MCs had lower Visuospatial and Executive Function/Working Memory but not Verbal Memory or Language composite scores.</AbstractText>This study is consistent with findings in sporadic Alzheimer disease of early problems with memory, visuospatial function, and particularly with executive function in PS1 mutation carriers. Depression, gender, and presence of an APOE epsilon4 allele did not demonstrate large influences on neuropsychological performance.</AbstractText> |
2,336,878 | GPs' opinions of their role in prenatal genetic services: a cross-sectional survey. | In the UK about 4.5% of the population carry cystic fibrosis, whilst in the inner city areas an even higher proportion carry one of the haemoglobin disorders such as thalassaemia. Couples who both carry the same recessive disorder have a 1 in 4 risk of an affected child in every pregnancy.</AbstractText>To assess GPs' confidence in their ability to provide initial prenatal advice for couples carrying common autosomal recessive disorders (either the cystic fibrosis or thalassaemia gene), and their opinions of different approaches for referral to prenatal diagnostic services for such at-risk couples.</AbstractText>A cross-sectional postal survey of all 644 GPs in 388 general practices in Nottinghamshire. Practices were randomly allocated to receive either the cystic fibrosis or the thalassaemia scenario survey. The survey questions predominantly used six-point Likert scales to assess confidence and opinions of prenatal services.</AbstractText>The questionnaire was returned by 62% (397) of GPs. Only 23% (91) were confident in providing prenatal advice to the at-risk carrier couples. GPs were more confident about advising cystic fibrosis carriers than thalassaemia carriers (P = 0.01). The least popular approach to prenatal service provision was direct referral to prenatal services after counselling with 52% (194) scoring this as useful, whilst 60.5% (233) of GPs scored referral to the obstetric services with the prenatal diagnosis organised by the obstetrician as useful.</AbstractText>GPs perceive that they lack the confidence to provide basic prenatal genetic advice to women at risk of the commonest recessive disorders, with particularly low confidence where the couple both carry thalassaemia. A significant knowledge gap was demonstrated by the poor awareness of the importance of rapid referral to prenatal diagnostic services.</AbstractText> |
2,336,879 | Analysis of LRRK 2 G 2019 S and I 2020 T mutations in Parkinson's disease. | Mutations in the leucine-rich repeat kinase 2 (LRRK 2), encoding dardarin protein, have been demonstrated to be linked to autosomal dominant Parkinson's disease (PD). In the present study the entire exon 41 of LRRK 2 gene was evaluated in a series of 174 PD patients recruited from Polish population, aged at the time of diagnosis 54.0+/-39.1 years, 21 of them had positive family history of PD with mean onset of the disease of 51.9+/-11.7 years as well as in 190 healthy controls aged 73.7+/-6.0 years. The mutations were evaluated by direct sequencing for mutations in exon 41 of LRRK 2 gene. In the studied patients no known mutations in exon 41 of LRRK 2 gene, including G 2019 S and I 2020 T were found, both in PD patients as well as in the controls. It can be concluded that the G 2019 S and I 2020 T mutations in exon 41 of LRRK 2 gene are rare causes of Parkinson disease in a Polish population. |
2,336,880 | Alpha-helical domain is essential for antimicrobial activity of high mobility group nucleosomal binding domain 2 (HMGN2). | To examine the antimicrobial spectrum and functional structure of high mobility group nucleosomal binding domain 2 (HMGN2).</AbstractText>OMIGA protein structure software was used to analyze the two-dimensional structure of HMGN2. Synthetic short peptides were generated for studying the relationship between function and structure. Prokaryotic expression vectors were constructed for the holo-HMGN2 and its helical domain. Their E coli-based products were also prepared for antimicrobial testing. The antimicrobial assay included minimal effective concentration, minimal inhibitory concentration, and minimal bactericidal concentration.</AbstractText>OMIGA protein structure software analysis revealed a transmembrane alpha-helical structure (the putative antimicrobial domain) located from position 18 to 48 of the HMGN2 protein sequence. The antimicrobial assay showed that the MIC of the recombinant holo-HMGN2 against E coli ML-35p (an ampicillin-resistance strain), Pseudomonas aeruginosa ATCC 27853 and Candida albicans ATCC 10231 were 12.5, 25, and 100 mg/L, respectively. Against the same microorganisms, the MIC of the synthetic HMGN2 alpha-helical domain were 12.5, 25, and 100 mg/L, respectively, that is, the same as with the recombinant form of HMGN2. In contrast, recombinant holo-HMGN2 was inactive against Staphylococcus aureus ATCC 25923. The synthetic N-terminal and C-terminal fragments of HMGN2 had no antimicrobial activity against E coli ML-35p, P aeruginosa ATCC 27853 or C albicans ATCC 10231.</AbstractText>HMGN2 showed potent antimicrobial activity against E coli ML-35p, P aeruginosa ATCC 27853 and, to some extent, against C albicans ATCC 10231, but was inactive against S aureus ATCC 25923 in these assay systems. Itos alpha-helical structure may be essential for the antimicrobial activity of HMGN2.</AbstractText> |
2,336,881 | Association of a -1997G-->T polymorphism of the collagen Ialpha1 gene with bone mineral density in postmenopausal Japanese women. | Genetic variants that affect collagen Ialpha1 metabolism may be important in the development of osteoporosis or osteoporotic fractures. A -1997G-->T polymorphism in the promoter of the collagen Ialpha1 gene (COL1A1) was shown to be associated with bone mineral density (BMD) for the lumbar spine in postmenopausal Spanish women. The relation of this polymorphism to BMD in Japanese women or men has now been examined in a population-based study. The subjects (1,110 women, 1,126 men) were 40 to 79 years of age and were randomly recruited for a population-based prospective cohort study of aging and age-related diseases. BMD for the lumbar spine, right femoral neck, right trochanter, and right Ward's triangle was measured using dual-energy x-ray absorptiometry. Genotypes for the -1997G-->T polymorphism of COL1A1 were determined with a fluorescence-based allele-specific DNA primer assay system. When all women were analyzed together, BMD for the lumbar spine and trochanter was significantly lower in subjects with the COL1A1 *G/*G genotype than in those in the combined group of COL1A1 *G/*T and COL1A1 *T/*T genotypes. When postmenopausal women were analyzed separately, BMD for the femoral neck and trochanter was also significantly lower in those with the COL1A1 *G/*G genotype than in those with the COL1A1 *G/*T genotype or those in the combined group of COL1A1*G/*T and COL1A1 *T/*T genotypes. BMD was not associated with -1997G-->T genotype in premenopausal women or in men. Multivariate regression analysis revealed that -1997G-->T genotype affected BMD at various sites with a variance of 0.46-0.62% for all women and 0.61-1.01% for postmenopausal women. The -1997G-->T genotype was not related to the serum concentration of osteocalcin, the serum activity of bone-specific alkaline phosphatase, or the urinary excretion of deoxypyridinoline or cross-linked N-telopeptides of type I collagen in men or in premenopausal or postmenopausal women. These results suggest that COL1A1 is a susceptibility locus for reduced BMD in postmenopausal Japanese women. |
2,336,882 | A genetic approach to the child with sensorineural hearing loss. | This article presents an overview of current topics related to the genetics of hearing loss. The review focuses on the approach toward a child with a sensorineural hearing loss of unknown etiology and the incorporation of genetic testing into the workup. Nongenetic causes of hearing loss are reviewed, as they are important in the differential diagnosis when considering a genetic basis for a child's hearing loss. The implications of universal newborn hearing screening and its implementation in many states are also addressed. Furthermore, important factors involved in the clinical diagnosis of the etiology of hearing loss, as well as factors relating to intervention and management of children with hearing loss are discussed. Finally, this review will consider genetic counseling for hearing loss and some of the issues important to the Deaf community. |
2,336,883 | Inherited thrombophilias and adverse pregnancy outcome: screening and management. | Inherited thrombophilias are a heterogenous group of conditions which have been implicated in a variety of pregnancy complications. Evidence is mounting that implicates these inherited disorders in a range of pregnancy outcomes, including recurrent miscarriage, late fetal loss, preeclampsia, abruptio placentae, and intrauterine growth restriction. The most commonly identified inherited thrombophilias consist of Factor V Leiden and the prothrombin gene mutation G20210A. Rarer inherited thrombophilic conditions include deficiencies of protein S, C and antithrombin. More recently, deficiency of protein Z has been linked to pregnancy complications, including preterm delivery. Clinical manifestations often are associated with the presence of more than one inherited thrombophilia, consistent with their multigenic nature. Some, but not all, studies investigating the use of heparin to prevent adverse pregnancy outcome have demonstrated a benefit. However, an adequate randomized trial is required to definitively determine whether heparin anticoagulation is the best prevention option in patients who harbor one or more inherited thrombophilias and are at risk for adverse pregnancy outcome. This review will summarize the association of thrombophilic conditions and obstetrical complications. |
2,336,884 | New directions in cytogenetic and molecular testing of the neonate. | The development of new diagnostic, and hence therapeutic possibilities, has brought the realization that genetic disease is now an integral part of medical practice. Advances in cytogenetic and molecular testing have drastically improved the ability to diagnose with certainty many previously unrecognized conditions. However, this advance in technology does not come without new questions. New tests are not always the most cost effective ones, some have significant diagnostic limitations, and others raise valid ethical issues surrounding the testing of minors. A working understanding of new advances in genetic diagnosis as well as their inherent limitations is crucial for the contemporary practitioner. |
2,336,885 | From genetics to genomics: using gene-based medicine to prevent disease and promote health in children. | The remarkable achievements of the Human Genome Project promise great opportunities for disease prediction, treatment, and prevention. In this paper, we discuss the continuum of genetic variation as medical practice begins to shift focus from the study of single genes (genetics) to the study of the entire genome (genomics). Pediatricians should anticipate an influx of genetic information and will need to become as facile in interpreting this type of predictive information as they are with other types of medical data, while recognizing the unique ethical, legal, and social implications of genetic testing in children. We discuss an approach to assist pediatricians in decision-making that emphasizes the need for knowledge about the analytic performance of genetic tests, their validity in predicting health outcomes, and the utility of the genetic information in improving health and preventing disease. |
2,336,886 | [Molecular bases of dystrophinopathies]. | Duchenne muscular dystrophy (DMD) is inherited in an X-linked recessive pattern and occurs at an incidence of 1 in 3500 male births, which means that it is a so-called "orphan" or rare disease (frequency < 1/2000). Yet it is one of the most frequent myopathies and is observed in all populations. We review here the spectacular advances made in our understanding of this disease since the identification in 1986 of the responsible gene. This gene encodes a subsar-colemmal component of the cytoskeleton, dystrophin. We consider the impact of this discovery on molecular diagnosis at the protein and DNA levels. Despite the time that has passed since, the discovery of the gene has not led to any treatment, and we review the therapeutic prospect. |
2,336,887 | Testing differential gene expression in functional groups. Goeman's global test versus an ANCOVA approach. | Single genes are not, in general, the primary focus of gene expression experiments. The researcher might be more interested in relevant pathways, functional sets, or genomic regions consisting of several genes. Efficient statistical tools to handle this task are of interest to research of biology and medicine.</AbstractText>A simultaneous test on phenotype main effect and gene-phenotype interaction in a two-way layout linear model is introduced as a global test on differential expression for gene groups. Its statistical properties are compared with those of the global test for groups of genes by Goeman et al. in a preliminary simulation study. The procedure presented also allows adjusting for covariates.</AbstractText>The proposed ANCOVA global test is equivalent to Goeman's global test in a setting of independent genes. In our simulation setting for correlated genes, both tests lose power, however with a stronger loss for Goeman's test. Especially in cases where the asymptotic distribution cannot be used, the stratified use of the ANCOVA global test shows a better performance than Goeman's test.</AbstractText>Our ANCOVA-based approach is a competitive alternative to Goeman's global test in assessing differential gene expression between groups. It can be extended and generalized in several ways by a modification of the projection matrix.</AbstractText> |
2,336,888 | Multiplicity issues in microarray experiments. | Discussion of different error concepts relevant to microarray experiments. Review of some commonly used multiple testing procedures. Comparison of different approaches as applied to gene expression data.</AbstractText>This article focuses on familywise error rate (FWER) and false discovery rate (FDR) controlling procedures. Methods under investigation include: Bonferroni-type methods and their improvements (including resampling approaches), modified Bonferroni methods, data-driven approaches, as well as the linear step-up method and its modifications. Particular emphasis lies on the description of the assumptions, advantages and limitations for the investigated methods.</AbstractText>FWER controlling procedures are often too conservative in high dimensional screening studies. A better balance between the raw P-values and the stringent FWER-adjusted P-values may be required in many situations, as provided by FDR controlling and related procedures.</AbstractText>The questions remain open, which error concept to apply and which multiple testing procedure to use. Although we believe that the FDR or one of its variants will be applied more often in the future, longterm experience with microarray technology is missing and thus the validity of appropriate multiple test procedures cannot yet be assessed for microarray data analysis.</AbstractText> |
2,336,889 | Preimplantation genetic diagnosis of Canavan disease. | Canavan disease is an autosomal recessive disorder which is relatively common in Ashkenazi Jews. It is characterized by developmental delay, severe hypotonia and early death, and is caused by a deficiency of aspartoacylase which is encoded by the ASPA gene. In Ashkenazi Jews, one major mutation (E285A) and one minor mutation (Y231X) account for the majority of cases. The objective of this study was to develop a preimplantation genetic diagnosis (PGD) protocol for Canavan disease.</AbstractText>Two carrier couples requested PGD for Canavan disease. In 1 couple each was a carrier of a different ASPA mutation (Y231X and E285A). In the other couple both were carriers of the minor mutation (Y231X). A single-cell duplex nested polymerase chain reaction (PCR) protocol was first developed on single leukocytes obtained from the known carrier parents. Following verification in single leukocytes, clinical PGD was offered to both couples.</AbstractText>We evaluated 115 single leukocytes from known carriers and found an allele drop out rate of 1.7% for the fragment harboring the Y231X mutation and 0% for the fragment harboring the E285A mutation. One cycle of PGD was performed in each family. In the first, 11 embryos were successfully analyzed and 4 were found to be affected. Two unaffected embryos were transferred, but no pregnancy resulted. In the other family, 4 embryos were analyzed, 1 was affected, 2 were heterozygotes and 1 was homozygous normal. Following transfer of 2 unaffected embryos, a singleton pregnancy resulted, currently ongoing at 18 weeks gestational age. Amniocentesis performed at 16 weeks confirmed the diagnosis.</AbstractText>Reliable PGD for Canavan disease is possible using a single-cell nested PCR approach.</AbstractText> |
2,336,890 | Attitudes about genetics in underserved, culturally diverse populations. | New medical discoveries regarding genetic susceptibility to common chronic diseases, and the decoding of the human genome have increased public attention to genetics. What information is understood and what attitudes exist towards genetics and genetic research have not been well examined in underserved, culturally diverse communities.</AbstractText>To better understand attitudes and beliefs towards genetics and genetic testing in these groups, we conducted eight focus groups with 55 patients and health care workers in New York City and Westchester, N.Y., in English, Spanish, and Chinese.</AbstractText>Focus group participants had limited understanding about genetics or genetic testing. Newborn screening was the least-known genetic issue, even among health care workers. Regardless of their cultural group, most participants expressed a desire for more information about genetics and genetic tests. Latinos and Chinese participants generally expressed positive attitudes towards genetic studies and genetic testing, with the possibility of preventing diseases cited as the main advantage. Black Americans and Non-Hispanic Whites reported mixed feelings about genetic research and genetic testing. Concerns expressed included: anxiety before receiving test results or waiting for a disease to develop, fear of genetic discrimination by health and life insurance companies and employers, not having the financial means to deal with genetic diseases in themselves or a sick child, concern that children and adults are having too many tests. Black Americans expressed the most concern for possibly harmful use of genetic information.</AbstractText>Minority populations of diverse cultures have limited knowledge about genetics and genetic testing, would like to have more information, and are not well reached by the current educational approaches. Participants knew the least about newborn screening, a test that is mandatory in the New York State. While genetic knowledge by minority populations was perhaps not different from the level of knowledge of consumers in general, minority populations are at particular risk of being left behind because of historically poor access to information and services.</AbstractText> |
2,336,891 | Attitudes and misconceptions about predictive genetic testing for cancer risk. | To describe awareness, knowledge, and attitudes about genetic testing for cancer risk among the general public.</AbstractText>Thirty-eight adults participated in focus groups in West Philadelphia, Pennsylvania. Participants' beliefs about what genetic testing is ranged from 'dianetics' to an accurate description of DNA analysis. Themes included misconceptions about genetic tests, the ability to gain control of one's life through genetic testing, anxiety that might be caused by testing, risk of insurance and employment discrimination, use of genetic information for racial or ethnic discrimination, concerns about medical information confidentiality and lack of informed consent.</AbstractText>Although there was some accurate understanding of what genetic testing is and how the results could be used, there also exist significant misconceptions. In many cases, misconceptions may be barriers to uptake of genetic testing. Dispelling these misconceptions is an important step in the translation of advances in human genomics into improvements in health.</AbstractText> |
2,336,892 | The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. | A relevant clinical problem in the treatment of ovarian cancer (OC) is the development of resistance to chemotherapy, frequently due to genetic variations in enzymes and receptors. Changes in the HER2 receptor have been associated with breast and ovarian cancers. The role of a polymorphism in the HER2 gene in the clinical outcome of OC patients was investigated in this study. We characterized DNA samples from 111 patients with OC treated with cisplatin and paclitaxel, using PCR-RFLP. Our results indicate that patients carrying the valine homozygotic genotype present a lower overall survival mean, suggesting a role for this polymorphism in the outcome of ovarian cancer patients. The G allele has been implicated in the formation of active HER2 receptors, with a more aggressive phenotype. We hypothesize that HER2 genotypes can be predictive biomarkers in ovarian cancer, contributing to a genetic individual profile of great interest in clinical oncology. |
2,336,893 | Factors increasing local recurrence in breast-conserving surgery. | From 20-year follow-up results of two pioneering randomized controlled trials demonstrating equal survival after mastectomy and breast-conservation therapy, recent high-quality, evidence-based clinical practice recommendations have been made. Breast-conservation therapy undoubtedly represents substantial progress for a better quality of life for women with early-stage breast cancer. However, lumpectomy is associated with a substantial proportion, approximately 10-20%, of local recurrence in long-term follow-up studies even after accounting for postoperative radiotherapy. Risk factors for local failure include margin status, young age and an extensive intraductal component. Young age and family history strongly suggest the need for genetic testing before initiation of treatment. Women with BRCA1 or BRCA2 mutations should be informed about the increased risk of contralateral breast cancer and ipsilateral failure after breast-conservation therapy. Bilateral mastectomy should also be offered as a treatment option. There is controversy over whether current effective adjuvant treatment, including chemotherapy and endocrine therapy, beyond appropriate local treatment as surgery and radiotherapy, can improve local control. Instead of debate over whether an ipsilateral tumor after breast-conservation therapy is local recurrence or a new primary cancer by analyzing conflicting data lacking strong evidence, efforts should be focused on reducing this risk irrespective of origin. Selecting women for breast-conservation therapy and achieving margin control can reduce ipsilateral failures. |
2,336,894 | Rare missense variants in ATP1A2 in families with clustering of common forms of migraine. | Migraine is a recurrent neurovascular disease. Its two most common forms-migraine without aura (MO) and migraine with aura (MA)-both show familial clustering and a complex pattern of inheritance. Familial hemiplegic migraine (FHM) is a rare monogenic subform caused by mutations in the calcium channel gene CACNA1A or the Na(+)/K(+)-ATPase gene ATP1A2. An involvement of FHM genes in the pathogenesis of common forms of migraine is not proven. We therefore systematically screened ATP1A2 in families with several members affected by MA and/or MO. We identified two novel missense alterations [c.520G>A (p.E174 K) and c.1544G>A (p.C515Y)] in two out of 45 families, which were not found in 520 control chromosomes. Functional studies of these variants in Xenopus oocytes by two-electrode voltage clamp measurements and radiochemical determination of ATPase activity showed that C515Y leads to a complete loss of function comparable with the effect of FHM-mutations whereas for E174 K no functional alteration could be found in the in vitro assays. In conclusion we propose that rare variants in ATP1A2 are involved in the susceptibility to common forms of migraine, because of 1) the absence of alterations in controls, 2) the particular pattern of segregation in both families, 3) the high conservation of mutated residues in Na(+)/K(+)-ATPases, 4) the functional effect of C515Y, and 5) the involvement of ATP1A2 in a monogenic form of migraine. |
2,336,895 | Gametophytic selection in Arabidopsis thaliana supports the selective model of intron length reduction. | Why do highly expressed genes have small introns? This is an important issue, not least because it provides a testing ground to compare selectionist and neutralist models of genome evolution. Some argue that small introns are selectively favoured to reduce the costs of transcription. Alternatively, large introns might permit complex regulation, not needed for highly expressed genes. This "genome design" hypothesis evokes a regionalized model of control of expression and hence can explain why intron size covaries with intergene distance, a feature also consistent with the hypothesis that highly expressed genes cluster in genomic regions with high deletion rates. As some genes are expressed in the haploid stage and hence subject to especially strong purifying selection, the evolution of genes in Arabidopsis provides a novel testing ground to discriminate between these possibilities. Importantly, controlling for expression level, genes that are expressed in pollen have shorter introns than genes that are expressed in the sporophyte. That genes flanking pollen-expressed genes have average-sized introns and intergene distances argues against regional mutational biases and genomic design. These observations thus support the view that selection for efficiency contributes to the reduction in intron length and provide the first report of a molecular signature of strong gametophytic selection. |
2,336,896 | Genetic variation of Polish endangered Biłgoraj horses and two common horse breeds in microsatellite loci. | Genetic variation of endangered Biłgoraj horses and two common Polish horse breeds was compared with the use of 12 microsatellite loci (AHT4, AHT5, ASB2, HMS2, HMS3, HMS6, HMS7, HTG4, HTG6, HTG7, HTG10, VHL20). Lower allelic diversity was detected in all investigated populations in comparison to other studies. Large differences in the frequencies of microsatellite alleles between Biłgoraj horses and two other horse breeds were discovered. In all polymorphic loci all investigated breeds were in the Hardy-Weinberg equilibrium. Mean Fis values and the results of a test for the presence of a recent bottleneck were non-significant in all studied populations. Comparable values of observed and expected gene diversity indicate no substantial loss of genetic variation in the Biłgoraj population and two other breeds. The lowest variability observed in the investigated group of Thoroughbred horses was confirmed. About 10% of genetic variation are explained by differences between breeds. Values of pairwise Fst and two measures of genetic distance demonstrated that Biłgoraj horses are distantly related to both common horse breeds. |
2,336,897 | The evolutionary dynamics of endogenous retroviruses. | Endogenous retroviruses (ERVs) are vertically transmitted intragenomic elements derived from integrated retroviruses. ERVs can proliferate within the genome of their host until they either acquire inactivating mutations or are lost by recombinational deletion. We present a model that unifies current knowledge of ERV biology into a single evolutionary framework. The model predicts the possible long-term outcomes of retroviral germline infection and can account for the variable patterns of observed ERV genetic diversity. We hope the model will provide a useful framework for understanding ERV evolution, enabling the testing of evolutionary hypotheses and the estimation of parameters governing ERV proliferation. |
2,336,898 | Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. | Structured treatment interruption (STI) may allow viral replication in the presence of decreased plasma drug levels, with risk of selection of resistance mutations.</AbstractText>For patients recruited for an STI study, genotypic resistance testing was performed at baseline (before receipt of any treatment), immediately before the STI, and 2 weeks after each interuption of therapy.</AbstractText>During 20 (18%) of 112 STI cycles (95% CI, 11%-26%), resistance mutations were selected; 6% of the mutations were de novo (i.e., not detected before the start of STI), and 12% were archived mutations (i.e., mutations already detected before the STI). Overall, resistance mutations during STI were selected in 9 (26%) of 35 patients; 5 (14%) of the mutations were de novo, and 4 (12%) were archived mutations. Mutations conferring resistance to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) were selected in 3 (23%) of 13 patients receiving NNRTI-based regimens (all mutations were de novo). Mutations conferring resistance to lamivudine were selected in 9 (50%) of 18 patients receiving lamivudine-containing regimens (4 [22%] were de novo, and 5 [28%] were archived mutations). Mutations conferring resistance to nucleoside reverse-transcriptase inhibitors (NRTIs), excluding the M184V mutation, were selected in 2 (6%) of 35 recipients of NRTIs (1 [3%] of these mutations was de novo, and 1 [3%] was an archived mutation. Finally, mutations conferring resistance to protease inhibitors were selected in none of the 22 patients receiving protease inhibitors. In most cases, de novo and archived mutations were selected during the first STI cycle, and their number did not increase during successive cycles. Plasma viral load decreased to undetectable levels in all the patients when the earlier drug regimen was reintroduced.</AbstractText>Genotypic mutations are selected during STI in a high proportion of patients (especially in patients receiving NNRTIs or lamivudine). Approximately one-half of selected mutations were archived mutations. Patients who had archived mutations did not have a higher risk of accumulating new mutations than did patients who were infected with wild-type virus before the STI.</AbstractText> |
2,336,899 | [Rapid onset of visual recovery following acute visual loss due to leber's hereditary optic neuropathy]. | Leber's hereditary optic neuropathy (LHON) is a maternally inherited disorder affecting the optic nerves in which the typical clinical presentation is subacute, painless, sequential visual loss in young adult males. Patients with LHON who have atypical clinical features may be initially misdiagnosed.</AbstractText>An 8-year-old boy developed an acute severe bilateral optic neuropathy associated with pain and mild optic disc edema. Molecular genetic testing of his mitochondrial DNA revealed two point mutations, T14484C and G15257A. His vision began to improve within one month of onset of visual loss and eventually recovered to 20/15 in both eyes. Four years previously, his oldest sister had acutely lost vision in both eyes at age 12 years. Her young age, female gender, the bilateral visual loss associated with pain, optic disc edema, absent family history of visual loss and negative workup were felt to be most consistent with a clinical diagnosis of idiopathic optic neuritis of childhood. Her visual recovery which began within two months of visual loss further supported the diagnosis. She was retrospectively re-diagnosed with LHON after her younger brother was genetically confirmed.</AbstractText>We describe two siblings with LHON whose time course from onset of visual loss to onset of visual recovery was unusually rapid. Because of other atypical features for LHON such as their young age at presentation, bilateral simultaneous visual loss and associated periorbital pain, their clinical profile appeared more typical of a demyelinating disease such as childhood optic neuritis. The first affected sibling (sister) was initially misdiagnosed. This report emphasizes that the clinical spectrum of LHON is variable and thus, LHON should be considered in any patient with an acute bilateral optic neuropathy, even in the absence of a positive family history. Correct diagnosis of this maternally inherited disorder is important for assessment of visual prognosis and appropriate genetic counseling.</AbstractText> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.